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Abstract
Reactive oxygen species (ROS) generated within cells or, more generally, in a tissue environment,
may easily turn into a source of cell and tissue injury. Aerobic organisms have developed
evolutionarily conserved mechanisms and strategies to carefully control the generation of ROS and
other oxidative stress-related radical or non-radical reactive intermediates (that is, to maintain
redox homeostasis), as well as to 'make use' of these molecules under physiological conditions as
tools to modulate signal transduction, gene expression and cellular functional responses (that is,
redox signalling). However, a derangement in redox homeostasis, resulting in sustained levels of
oxidative stress and related mediators, can play a significant role in the pathogenesis of major
human diseases characterized by chronic inflammation, chronic activation of wound healing and
tissue fibrogenesis. This review has been designed to first offer a critical introduction to current
knowledge in the field of redox research in order to introduce readers to the complexity of redox
signalling and redox homeostasis. This will include ready-to-use key information and concepts on
ROS, free radicals and oxidative stress-related reactive intermediates and reactions, sources of
ROS in mammalian cells and tissues, antioxidant defences, redox sensors and, more generally, the
major principles of redox signalling and redox-dependent transcriptional regulation of mammalian
cells. This information will serve as a basis of knowledge to introduce the role of ROS and other
oxidative stress-related intermediates in contributing to essential events, such as the induction of
cell death, the perpetuation of chronic inflammatory responses, fibrogenesis and much more, with
a major focus on hepatic chronic wound healing and liver fibrogenesis.
Background
From oxidative stress to redox homeostasis and redox 
signalling
Molecular oxygen (O2) is essential for the survival of
human beings and, more generally, of all aerobic organ-
isms. Aerobic energy metabolism relies on oxidative phos-
phorylation, a crucial process by which the oxido-
reduction energy of mitochondrial electron transport is
eventually converted to the high-energy phosphate bond
of ATP. Aerobic organisms use O2 as the final electron
acceptor for mitochondrial cytochrome c oxidase, which,
in turn, represents the terminal functional element of the
mitochondrial multicomponent NADH dehydrogenase
enzymatic complex, which is able to catalyze the four-
electron reduction of O2, leading then also to H2O forma-
tion (Figure 1). During mitochondrial oxidative phospho-
rylation and other electron transfer reactions, however,
partially reduced and highly reactive O2  metabolites,
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ROS are generated in biological systems through a number of interrelated reactions Figure 1
ROS are generated in biological systems through a number of interrelated reactions.
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including superoxide anion (O2
￿-), hydrogen peroxide
(H2O2) and hydroxyl radical (￿OH), can be formed within
cells. These reactive O2 metabolites are usually collectively
referred to as 'reactive oxygen species' (ROS) and their
generation in a biological environment exposes most liv-
ing organisms to the so-called 'oxygen paradox': oxygen is
necessary for life but it is also potentially hazardous since
ROS may easily become a source of cell and tissue injury,
as was recognized by early pioneers of free radical research
[1-9]. However, as a natural consequence of this paradox,
aerobic organisms have developed evolutionarily con-
served mechanisms and strategies to carefully control the
generation of ROS and other oxidative stress-related radi-
cal or non-radical reactive intermediates (that is, to main-
tain redox homeostasis), as well as to 'make use' of these
molecules under physiological conditions as tools to
modulate signal transduction, gene expression and cellu-
lar functional responses (the concept of redox signalling)
[10-23].
At present, redox research is at the forefront of biomedical
research in view of the expanding knowledge on the roles
that increased and/or sustained levels of oxidative stress
and related mediators have been described to play in
major human diseases, including atherosclerosis, diabetes
and cardiovascular diseases [14,24-29], cancer [30,31],
neurodegenerative disorders [32-34], chronic liver [35-
38] and lung diseases [39-41], to name just a few. Most of
the conditions in which the role of oxidative stress and
related mediators has been characterized belong to what
one may define as chronic inflammatory/fibrogenic dis-
eases, often involving chronic activation of wound heal-
ing.
About this review
This review has been designed as an attempt to offer a
comprehensive, but not hyper-specialized, critical intro-
duction to current knowledge in the field in order to intro-
duce readers to the fascinating complexity of redox
signalling and redox homeostasis regulation, with a major
focus on chronic wound healing and liver fibrogenesis.
This review will then offer a sequence of ready-to-use key
information and concepts on major types of ROS, free
radicals and oxidative stress-related reactive intermediates
operating in living organisms, their sources in mamma-
lian cells and tissues, and antioxidant defences. Along
these lines, this review will not intentionally deal with all
the details but, whenever possible, the interested reader
will find indications for highly recommended and more
detailed and specialized reviews and articles on specific
topics.
ROS, free radical and non-radical reactive 
intermediates in biological materials
Reactive oxygen species
ROS is a generic collective term indicating a number of
active and reactive partially reduced O2 metabolites. Some
of them, such as O2
￿- and ￿OH, can be defined as true free
radicals, which are reactive molecular species with an
impaired electron in their outer orbital. Free radicals are
paramagnetic and reactive chemical entities that can
undergo redox reactions by interacting with surrounding
molecules in order to regain the more stable non-radical
condition. Other ROS, such as H2O2, are more properly
pro-oxidant non-radical agents. Indeed, O2
￿-,  ￿OH and
H2O2 are by far the most relevant in physiological or
pathophysiological conditions. Crucial information on
major ROS, their sources and reactions are briefly summa-
rized below and in Figures 1 and 2.
The superoxide anion O2
•-
O2
￿- is the result of univalent reduction of triplet state
molecular oxygen; its intracellular generation can prima-
rily occur non-enzymatically by the intervention of redox
components such as the semi-ubiquinone compound of
the mitochondrial electron transport chain [8,42] or
through the intervention of enzymes like NADPH-oxidase
(NOX) [43,44], xanthine-oxidase and others (Figure 2;
and see below) or in auto-oxidation reactions [7,8,42].
Major features of O2
￿- include: it is a relatively unreactive
intermediate, being able to act at best as a mild reactant in
physiological conditions and, indeed, only the interaction
with nitric oxide (NO) to give peroxynitrite is able to
transform superoxide into a very reactive intermediate; in
living tissue, O2
￿- can be converted into H2O2 enzymati-
cally by superoxide-dismutase (SOD) isoforms [42], or
non-enzymically [8]; and it has a rather poor ability to
cross biological membranes [42].
Hydrogen peroxide
H2O2 represents a two-electron reduction state of molecu-
lar oxygen and originates mainly from enzymatic dismu-
tation catalysed by superoxide dismutase (SOD) isoforms.
H2O2 can also originate from non-enzymic dismutation
of O2
￿- as well as from direct reduction of O2[8,42]. Major
features of H2O2 include: it can easily diffuse across bio-
logical membranes; it is a non-radical potent oxidizing
agent; in aqueous solutions it can oxidize or reduce sev-
eral inorganic ions [42,45]; it can usually be removed by
either catalase or glutathione peroxidase; it can give rise to
the very reactive and damaging ￿OH when interacting
with O2
￿- (Figure 1; Haber-Weiss reaction), or in the pres-
ence of divalent metal ions like iron and copper ” when
Fe2+ is present, the latter reaction is also defined as Fen-
ton's reaction (or Fe2+-catalysed Haber-Weiss reaction)
[42]; and myeloperoxidase of phagocytic cells use it to
form hypochlorite (HOCl), a highly reactive compoundFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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Major cellular sources of ROS in living cells Figure 2
Major cellular sources of ROS in living cells.
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able to oxidize thiol groups, amino groups and methio-
nine in proteins.
Hydroxyl radical
￿OH is a three-electron reduction state of O2 formed dur-
ing Haber-Weiss or Fenton reactions or by decomposition
of peroxynitrite. ￿OH has a very short half-life (10-9 s) and
high reactivity. As such, in biological systems it does not
diffuse from the site of generation and can rapidly damage
any surrounding macromolecules, including: amino
acids, potentially leading to protein inactivation/denatur-
ation; carbohydrates, with degradation; lipids, leading to
lipid peroxidation; and nucleic acids, leading, for exam-
ple, to the formation of adducts with deoxyguanidine (8-
OH-dG adducts, a reliable marker of ROS-dependent
damage to DNA) and, potentially, to mutations.
Major reactions of ROS and other related free radicals
Figure 1 offers a summary of most relevant reactions lead-
ing to the generation of ROS or to their transformation
into other reactive intermediates or inactive molecules.
Reactions 1 to 12 have been already described, so we men-
tion here only reactions 13 to 16. Reaction 13 is a 'starting'
reaction, leading to the generation of an organic radical,
R￿, as a consequence of the interaction of ￿OH with an
organic carbon-hydrogen bond. Peroxides, peroxyl-radi-
cals as well as alkoxyl-radicals (reactions 14 to 16) can be
generated during on-going oxidative stress as, for exam-
ple, during lipid peroxidation.
Intracellular sources of ROS
In living cells ROS can be generated by several sources, but
without any doubt the most relevant are those described
in Figure 2.
Mitochondria
Approximately 1”5% of electrons 'flowing' through the
electron transport chain can be diverted to form O2
￿- at the
levels of complex I (NADH/ubiquinone oxidoreductase)
and complex III (ubiquinol/cytochrome c oxidoreduct-
ase). O2
￿- is then usually converted by mitochondrial SOD
into H2O2, which can cross mitochondrial membranes to
reach the cytoplasm [8,42].
NADPH oxidase
NOX is present in both professional phagocytic cells
(macrophages, neutrophils and eosinophils) and non-
phagocytic cells and plays a crucial role in different dis-
eases [43,44,46], including chronic liver diseases (CLDs)
[47,48]. The classic phagocytic NOX is formed by the two
membrane bound components p22phox and gp91phox/
Nox2 (comprising the flavocytochrome b558) and four
cytosolic components (p40 phox, p47phox, p67phox and
the GTPase Rac1/2), which, following stimulation of
phagocytic cells, are recruited to the plasma membrane
where they interact with Cyt b558, leading to increased
activity and then ROS generation. The NOX of non-
phagocytic cells is similar in structure and function, with
gp91phox/Nox2 being replaced by another member of
the same family of proteins (usually by Nox2 homologues
Nox1, Nox3, Nox4, Nox5 or Duox1/2). The main differ-
ence, relevant for redox signalling, is that non-phagocytic
NOX is constitutively active, producing a very low level of
ROS and increasing both its activity and ROS generation
in response to a number of factors and conditions.
5-Lipoxygenase
5-Lipoxygenase (5-LOX) is a mixed function oxidase
involved in the synthesis of leukotrienes from arachidonic
acid in response to essentially the same stimuli that are
able to stimulate NOX, particularly growth factors and
cytokines. The latter mediators lead to membrane ruffling
and the generation of superoxide, and then H2O2,
through the intervention of the small GTPase Rac1 and a
SOD isoform [14-18,49].
Other enzymes
ROS can also be generated enzymatically in many subcel-
lular compartments by several oxidases, peroxidases, and
mono- and di-oxygenases as well as by isoforms of the
cytochrome P450 superfamily. Here it seems relevant to
mention xanthine oxidase [42,50], nitric oxide synthase
[51], cyclooxygenase [42,52] and other NAD(P)H
dependent oxido-reductases, which are all able to gener-
ate primarily O2
￿-. Similarly, peroxisomal oxidases [52]
(glycolate oxidases, D-amino oxidases, ureate oxidases,
fatty acid-CoA oxidases and L-α-hydroxyacid oxidases)
can generate H2O2 when metabolizing various substrates.
Also, lysyl oxidase [52], the enzyme catalysing the forma-
tion of the aldehyde precursors of cross-links in collagen
and elastin, can give rise to H2O2.
The process of lipid peroxidation and the generation of 
non-radical intermediates
Lipid peroxidation (Figure 3) is a term commonly used to
indicate oxidative decomposition of the ω-3 (22:6) and ω-
6 (18:2, 20:4) polyunsaturated fatty acids of membrane
phospholipids [19,42]. This process, which is very com-
mon in pathological conditions [21-23,42], is usually ini-
tiated by the interaction of a ROS or other free radical with
polyunsaturated fatty acids and exacerbated by the pres-
ence of divalent metal ions. This reaction leads to the for-
mation of lipid radicals (L￿) that, in turn, can react with
available O2 to generate lipid peroxyl radicals (LOO￿).
From this point the propagation phase of this chain reac-
tion occurs, whereby LOO￿ interacts with other lipid mol-
ecules, resulting in the generation of lipid hydroperoxides
(LOOH). These in turn undergo a degradative breakdown,
leading to the generation of other radical species (LO￿
and LOO￿) that further propagate lipid peroxidation, andFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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Lipid peroxidation and the formation of non-radical intermediates Figure 3
Lipid peroxidation and the formation of non-radical intermediates.
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to several aldehydic end-products, such as malonyldialde-
hyde (MDA) and 4-hydroxy-2,3-alkenals (HAKs) of differ-
ent chain lengths, [19,42] as well as to F2-isoprostanes
[53]. 4-Hydroxy-2,3-nonenal (HNE), the most active bio-
logical and pathophysiological HAK [23-25], and F2-iso-
prostanes (so defined because of their PGF2-like structure)
are relatively stable and lipid soluble compounds that can
diffuse from the site of generation and easily cross biolog-
ical membranes. Moreover, as proposed more than 25
years ago for HNE [23-25,35,54] and more recently for F2-
isoprostanes [55,56], these non-radical species can also
act as mediators that are able to affect redox state, signal
transduction and cell responses. Detection of HNE or F2-
isoprostanes in biological fluids or tissues is today consid-
ered one of the best ways to evaluate in vivo on-going oxi-
dative stress [57].
Nitric oxide and reactive nitrogen species
NO is a small hydrophobic molecule that crosses cell
membranes without needing channels or receptors [58]. It
is generated by NO synthase (NOS) isoforms through the
conversion of L-arginine to citrullin. Three types of NOS
have been identified: endothelial NO synthase (eNOS),
which is bound to plasma membranes and known to be
strongly activated by the entry of calcium through mem-
brane-bound receptors [59]; inducible NO synthase
(iNOS), which was first identified in macrophages and
then in other cells, including hepatocytes, is known to be
up-regulated by pro-inflammatory cytokines and/or
lipopolysaccharide (LPS), and is able to generate low lev-
els of NO compared with the other NOS isoforms; and
neuronal NO synthase (nNOS) (Figure 4).
NO exerts physiological effects by controlling vascular
tone, cell adhesion, vascular permeability and platelet
adhesion [12,13,15,60]. It also exerts several potentially
toxic effects, although many of these are more likely medi-
ated by oxidation products included in the definition
'reactive nitrogen species' (RNS). In particular, NO is able
to rapidly react with O2
￿- to form the much more powerful
oxidant peroxynitrite (ONOO-). Indeed, neither O2
￿- nor
NO are particularly toxic in vivo because of efficient sys-
tems able to minimize their accumulation [61,62]: O2
￿- is
removed by SOD isoforms whereas NO is removed as a
consequence of its rapid diffusion through tissues [63].
Under pro-inflammatory conditions, simultaneous pro-
duction of O2
￿- and NO can be strongly activated and sig-
nificant amounts of ONOO- are generated, which may
cause significant injury to different cellular structures.
Peroxynitrite
ONOO- (see [58] and references therein) is a strong oxi-
dant able to react directly with thiol groups, iron-sulphur
centres and the active site -SH groups in tyrosine phos-
phatases. In physiological conditions, the production of
ONOO- is quite low and oxidative injury is minimized by
endogenous antioxidant defences. When increased in
pathological conditions, ONOO- can act either as a direct
oxidising species or indirectly by decomposing into highly
reactive radicals. When ONOO- acts as an oxidant, it pro-
duces nitrite and a hydroxide ion rather than isomerising
to nitrate (Figure 4) and can react with proteins (tyrosine
nitration or direct reactions with specific amino acids),
lipids (lipid peroxidation) and nucleic acids (oxidative
modifications in nucleobases). ONOO- can also interact
with mitochondria, reaching them from extra-mithocon-
drial compartments or being locally produced through
the interaction of NO (generated by the mitochondrial
NOS) and O2
￿-. Mitochondrial toxicity of ONOO- results
from direct oxidative reactions of principal components
of the respiratory chain or from free radical-mediated
damage. Persistent generation of significant levels of
ONOO- can lead to the induction of cell death, either
apoptosis or necrosis (Figure 5; see also 'Mitochondria,
nitric oxide, RNS and cell death' below).
How ROS and other oxidative stress-related reactive 
intermediates interact with biological macromolecules
ROS, NO, HAKS and other free-radical or non-radical
reactive intermediates may interact with relevant biologi-
cal macromolecules [7-9,14,15,19,21,58], events that can
easily lead to cytotoxic/damaging consequences or con-
tribute to redox regulation and signalling.
ROS and other pro-oxidants
ROS and other pro-oxidants can interact with virtually any
macromolecule of biological interest. Their interaction
with DNA can lead to oxidative damage, strand breaks
and the formation of adducts (such as 8-hydroxy-deoxy-
guanidine (8-OH-dG)). By interacting with polyunsatu-
rated fatty acids in membrane phospholipids, ROS and
reactive pro-oxidants can elicit peroxidation of lipids and
their subsequent degradation and fragmentation. When
interacting with proteins, ROS may lead to: (a) oxidation
of critical amino acid residues, for example, the thiol
group of cysteine; (b) formation of intra-molecular
disulfide bonds (-S-S-); (c) thiol/disulfide changes leading
to either formation or disruption of inter-molecular
disulfide bonds between homo- or hetero-dimers; (d) for-
mation of di-tyrosine and protein cross-linking; and (e)
iron and copper metal ions can lead to the formation of
OH radicals in a Fenton reaction ” this can extensively
damage target proteins, leading to their ubiquitination
and proteasomal degradation. Reactions (a-c) can either
lead to functional inactivation of the target protein or (c)
convert a protein between its active and inactive states.
Reactions (d) and (e) can lead to the formation of new
antigens that the immune system may recognize as non-
self.Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
Page 8 of 58
(page number not for citation purposes)
Reactions leading to generation of NO and RNS Figure 4
Reactions leading to generation of NO and RNS.
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Reactions of peroxynitrite leading to either apoptotic or necrotic cell death Figure 5
Reactions of peroxynitrite leading to either apoptotic or necrotic cell death. NO and RNS may potentially prevent hepatocyte 
apoptosis as well as promote either necrotic or apoptotic cell death. The following mechanisms have been proposed. With 
regard to NO, RNS and prevention of apoptosis, the main molecular mechanisms resulting in an anti-apoptotic effect, related 
to S-nitrosating species, include [237-239]: stimulation of guanylate cyclase, leading to increased cyclic guanine monophosphate 
levels; the evolutionarily conserved inhibition of caspases by potentially reversible S-nitrosation of a critical cysteine residue at 
the caspase active site; activation of the Ras/Erk1/2 pro-survival pathway, which may result in activation of mitogen and stress 
activated kinase 1 (MSK1) and pp90 ribosomal S6 kinase (RSK), which in turn may inactivate the pro-apoptotic protein Bad or 
up-regulate anti-apoptotic proteins of the Bcl-2 family [237]; RNS also possibly acting by inhibiting leukocyte adhesion through 
S-nitrosation of critical -SH groups exposed by activated neutrophils and macrophages [240]. NO and RNS may prevent or 
promote cell death in relation to intracellular and intramitochondrial (because of mitochondrial NOS) levels of GSH and the 
concomitant cellular levels of transition metal ions. Moreover, NO may also lead to up-regulation of heme oxygenase 1 (HO-
1) in hepatocytes and this may serve as a cytoprotective event [237,238]. The dark (that is, damaging) side of NO and RNS: in 
the presence of higher levels of ROS, the right NO/superoxide ratio or levels of molecular oxygen, NO may lead again to gen-
eration of highly reactive RNS, such as N2O3 or ONOO- at levels that are able to induce more aggressive oxidation, nitrosa-
tion/S-nitrosation and nitration of different biological macromolecules, potentially leading either to necrotic or apoptotic cell 
death. If NO-dependent pro-apoptotic mechanisms are concerned, the following have been shown to have a major role, with 
some again depending on S-nitrosating species: RNS and so called NO+ -carriers (nitrosating species) may result in activation of 
JNK, which, as previously reported for ROS, may sustain induction of apoptosis; NO, if generated at high levels in mitochon-
dria, may result in ubiquinol auto-oxidation with concomitant production of superoxide, hydrogen peroxide and ONOO-, spe-
cies that may be responsible for irreversible damage to complexes I and II of the respiratory chain, inhibition of ATP synthesis 
and eventually cytochrome c release and induction of caspase-dependent apoptosis. It should also be noted that, in the pres-
ence of significant redox stress, NO can potentiate damaging effects, resulting in a scenario of necrotic cell death rather than 
apoptosis. This is likely to occur particularly when the redox state is significantly affected, as in conditions resulting in depletion 
of GSH or significant alterations of the GSH/GSSG ratio.
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Nitric oxide and reactive nitrogen species
RNS such as ONOO- [58] can easily lead to oxidation and
formation of strand breaks when reacting with nucleic
acids or to lipid peroxidation when interacting with mem-
brane lipids. Again, RNS may simply lead to oxidative
modification of proteins or to more selective reactions by
nitrosation or nitration (Figure 5).
4-Hydroxy-2,3-nonenal
HNE, an aldehydic end product of lipid peroxidation, can
exert both cytotoxicity as well as signalling modulation by
forming Michael type adducts on lysine, cysteine or histi-
dine residues [19-23]. HNE and other HAKs can also
interact with nucleic acids, leading to formation of DNA
adducts or even to strand breaks and genotoxicity. HNE
may also operate by eliciting intracellular generation of
ROS when interacting with mitochondria [23].
Antioxidant defences
Antioxidant defences rely on the sum of those mecha-
nisms that nature has developed to protect biological tis-
sues from ROS and other oxidants and from lipid
peroxidation (Figures 6, 7, 8. With respect to the 'hepatic'
focus of this review, the reader should note that all clinical
and experimental conditions of CLDs (that is, those lead-
ing to fibrosis/cirrhosis) have in common a sharp and sig-
nificant decrease in antioxidant defences (reviewed in
[35,36]). More details on antioxidant defences can be
found in [42,64-66].
Protection from ROS and oxidants
The following categories of naturally occurring compo-
nents may be defined.
Antioxidant enzymes
This group of antioxidant enzymes includes 'major'
enzymes such as catalase, glutathione peroxidase (GPX)
isoforms and SOD isoforms. Catalase and GPX isoforms
are responsible for the removal of H2O2 as well as other
organic hydroperoxides, whereas SOD isoforms operate
by transforming O2
￿- into H2O2 (Figure 7).
Protection by small molecules
Small molecules involved in protection from ROS and
oxidants include ascorbic acid, reduced glutathione
(GSH) and uric acid. Ascorbic acid (vitamin C) is a cofac-
tor for several enzymes that has the ability to act as an
electron donor and then as a reducing agent; ascorbate
can also scavenge (that is, interact directly with) ￿OH but
one has to briefly mention that, depending on the overall
concentration, ascorbate may become deleterious by
reducing Fe3+ to Fe2+ and, in the presence of H2O2, lead to
the generation of significant amounts of ￿OH. GSH is a
hydro soluble tripeptide acting as a substrate for H2O2-
removing enzymes such as GPX and dehydroascorbate-
reductase as well as a scavenger of ￿OH (leading to the
thiyl radical GS￿, which is not harmless) or as a thiol in
regenerating the oxidized -SH groups of proteins; Figure 6
also shows the essential reaction of GSSG reductase,
which recovers GSH. Uric acid, present in blood plasma,
has been reported to scavenge singlet oxygen, ￿OH and
peroxyl radicals.
Protection by sequestration of metal ions
Transition metal ions like iron and copper can exacerbate
ROS generation. Ferritin, transferrin, ceruloplasmin, met-
allothionein and lactoferrin can thus be seen not only as
relevant for their respective role in metal homeostasis but
also as molecules that, by 'sequestering' redox active metal
ions, may prevent ROS production via the Fenton reac-
tion.
Thioredoxin and glutaredoxin systems
Thioredoxins (Trxs, including Trx-1 and Trx-2) [65,66] are
12 kDa proteins with a catalytic site containing two
cysteine residues that can be oxidized reversibly to form
disulfide bridges. Trxs undergo NADPH-dependent reduc-
tion by Trx-reductase and, in turn, they can reduce oxi-
dized cysteine groups on proteins. Through this
intramolecular disulfide-thiol exchange, Trxs can act as
hydrogen donors, contributing to the control of redox
state. Trxs (mainly Trx-1) may supply reducing equiva-
lents to a number of Trx peroxidases (peroxiredoxins) and
also play a role in redox signalling by modulating kinases
or transcription factors by forming heterodimers with
them.
Glutaredoxins (Glrxs, the cytosolic Glrx-1 isoform and
Glrx-2, the latter existing as both mitochondrial and
nuclear isoforms) [66] also belong to the Trx superfamily
of thiol/disulfide exchange proteins and act as reductants
of protein-SG mixed disulfides. Similar to what was
described for the Trx system, Glrxs have a role in redox reg-
ulation and the Glrx system is composed of Glrx isoforms,
GSH reductase, GSH and NADPH.
Protection from lipid peroxidation: natural and synthetic 
antioxidants
According to Halliwell and Gutteridge [64] "an antioxi-
dant is any substance that, when present at low concentra-
tions compared to those of an oxidizable substrate, is able
to significantly delay or inhibit oxidation of that sub-
strate." Of course, this generic definition also includes pri-
mary antioxidants (free radical scavengers able to interact
directly with and/or to block the initiating free-radical,
such as mannitol) and synthetic molecules able to bind
metal ions (for example, desferrioxamine). However, sev-
eral authors, when using the word 'antioxidant', have in
mind the so-called 'chain breaking' or 'secondary antioxi-
dants', with α-tocopherol (vitamin E) being the naturallyFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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occurring prototype. These natural or synthetic molecules
have a chemical structure (Figure 8) able to intercept rad-
ical intermediates produced during on-going lipid perox-
idation, such as peroxyl or alkoxyl radicals, thus
preventing (that is, 'breaking') the perpetuation of hydro-
gen abstraction in the chain reaction. Figure 6 offers an
Antioxidant (chain breaking) action of α-tocopherol and its recycling through ascorbate and GSH Figure 6
Antioxidant (chain breaking) action of α-tocopherol and its recycling through ascorbate and GSH.
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Overview of antioxidant enzymes Figure 7
Overview of antioxidant enzymes.
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overview of the reactions involving α-tocopherol, includ-
Chemical structures of the most common chain-breaking antioxidants Figure 8
Chemical structures of the most common chain-breaking antioxidants.
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ing its re-cycling based on the involvement of GSH and
ascorbate.
A number of additional and useful concepts regarding
antioxidants (whether enzymic or not) should be consid-
ered: antioxidants binding metal ions are not usually con-
sumed during the course of reaction; antioxidants able to
decompose peroxides may be consumed or not, depend-
ing on their nature (for example, as enzymes GPXs are not
consumed); chain breaking ” as well as primary ” antioxi-
dants are usually consumed during on-going oxidative
stress; many antioxidants have multiple mechanisms of
action; some antioxidants (tocopherols, ubiquinol, caro-
tenoids and flavonoids) will exert their effects in a lipid
phase (that is, at the level of biological membranes)
whereas others will do so in an aqueous phase (ascorbate,
urate, GSH and other thiols).
Redox homeostasis, redox signalling, redox 
sensors and redox-dependent transcriptional 
regulation in mammalian cells: the good, the bad 
and the ugly
Redox signalling is a definition that can be used to indi-
cate any physiological or pathophysiological condition in
which a process can be regulated or modulated by a signal
that is delivered through redox chemistry [14-18]. When
significant levels of ROS are generated in a biological sys-
tem (that is, altering redox homeostasis), 'redox signal-
ling' then represents the response or part of the response
designed to 'reset' the original state of equilibrium. As in
any complex system reacting to the presence of defined
reactants, single cells and multicellular organisms have
developed highly specific redox sensors and mechanisms
that form the basis of oxidant scavenging and ROS signal-
ling systems.
Principles of redox homeostasis
To introduce the concept of redox homeostasis one can
refer to the scenario depicted in Figure 9 and to the intui-
tive concept of oxidant/antioxidant balance, which is still
the simplest way to begin understanding the complexity
of redox mechanisms.
Physiological conditions or unstimulated cells
Under physiological conditions, relatively low amounts
(steady-state levels) of ROS, free radicals and other reac-
tive intermediates are produced as a result of a dynamic
balance between the rate of their generation and removal.
Redox homeostasis is primarily controlled by catalase,
Trxs, SODs and GPXs, as well as by naturally occurring
antioxidants like GSH, vitamin E, β-carotene, ascorbate,
urate, and many others. However, enzymes and natural
antioxidants that are highly specific are present at rela-
tively low concentrations; the antioxidant arm of the so-
called oxidant/antioxidant balance is significantly imple-
mented by less specific or efficient, but much more abun-
dant, actors that are represented by amino acids, peptides
and proteins [14-18,42,65,66]. Indeed, almost all amino
acids may serve as molecular targets for pro-oxidants
(cysteine, tyrosine, tryptophan and histidine being the
most sensitive to oxidants) and the intracellular concen-
trations of free amino acids reach levels as high as 10-1 M.
Oxidized proteins may offer an additional contribution:
oxidative attack on proteins can lead to inactivation, frag-
mentation, aggregation of fragments and/or increased
susceptibility to proteolysis. Proteolytic degradation of
oxidized proteins is mainly due to 20S proteasome and it
has been proposed that oxidatively fragmented and/or
misfolded proteins have an increased ROS scavenging
activity than normal, non-oxidized proteins [67-69]. In
practical terms, cells in which very low levels of ROS are
generated (a baseline-like or steady state condition, as in
Figure 9a) do not suffer a significant imbalance in pro-oxi-
dants versus antioxidant defences and do not respond by
means of a redox signalling.
Cells exposed to an 'acute' and/or 'isolated' versus chronic generation 
of ROS
Whenever redox homeostasis is significantly disturbed ”
by an increase in ROS generation, by a decrease in one or
more antioxidants or by a change in the thiol/disulfide
redox state ” redox signalling can be elicited [14-18].
Three different scenarios, depending on the absolute
intracellular levels of ROS and other reactive species or the
temporal length of the alteration, may be envisaged (Fig-
ure 9b).
In the first scenario, the increase in ROS is relatively low
and transient (Figure 9b1). In these conditions, the shift
in redox balance will be limited and redox signalling will
operate through redox-sensitive signalling pathways and
transcription factors [14-18] in order to up-regulate genes
encoding products that will reset redox homeostasis
(enzymes, Trxs and Glrxs, the cystine transport system to
sustain the production of GSH, and so on).
In the other two scenarios, oxidative stress is more severe
(Figure 9b2 and 9b3). During acute tissue injury or in tis-
sues undergoing chronic injury, levels of intracellular ROS
and other reactive intermediates may be very high and/or
persistently increased within cells. The 'oxidative stress
response' may not be sufficient to contain disturbances
and reset the original redox homeostasis. Depending on
several factors (that is, the specific agent or condition
involved, the overall severity of the injurious process, and
so on) this may cause at least two scenarios. Levels of ROS
or reactive intermediates may be high enough within the
cells to significantly damage macromolecules or alter cel-
lular structures and functions, eventually leading to irre-
versible injury and cell death (Figure 9b2). If levels ofFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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Alteration of redox homeostasis, redox signaling and cellular responses Figure 9
Alteration of redox homeostasis, redox signaling and cellular responses. Figure 9a: cells under physiological conditions in the 
absence of redox-dependent responses. Figure 9b: cells in which a significant level of intracellular ROS generation occurs as a 
moderate and transient change in redox state (b1), as a severe and irreversible change leading to cell death (b2) or as a chronic 
shift in redox state (b3).
a) Cells under physiological conditions
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oxidative stress are significantly higher but are not able to
induce irreversible cell damage, as may occur in condi-
tions of chronic injury, cells and/or tissues may still reach
an equilibrium or, as elegantly defined by Dröge [15], a
'quasi-stable state' (Figure 9b3). This definition implies a
shift of the intracellular redox state to higher levels of ROS
and a chronically deregulated state in which redox signal-
ling can up-regulate patterns of gene expression and cell
responses that are believed to significantly contribute
and/or sustain the development of chronic diseases and
even cancer progression [15,70]. Of course, the scenario
given in Figure 9b1”b3 is a didactic one and in a tissue
undergoing chronic injury, inflammation and wound
healing the three conditions are likely to coexist, with an
overall scenario in which the development of the disease
results from the sum of both ROS-dependent damaging
effects and changes in gene expression.
Redox sensors and the basis of redox-dependent 
transcriptional regulation
At this point one should move beyond the simple concept
of oxidant/antioxidant balance by introducing the more
refined notion of redox sensors as well as the principles of
redox-dependent regulation of transcription. The key
messages in this area (for more details see [18,71]) can be
summarized as follows.
The definition of 'redox sensors'
A redox sensor is a specialized redox-sensitive protein that
is able to 'sense' or 'measure' intracellular levels of ROS by
a redox-based mechanism affecting one or more residues/
domains within its three-dimensional structure, and to
transform the redox change into a specific setting for anti-
oxidant activity-related transcription and, particularly for
mammalian cells, much more.
Redox sensors in prokaryotic cells and yeast
Redox sensors were first described in bacteria, including
the OxyR and SoxR redox sensitive transcription factors,
the chaperon molecule Hsp33, the oxygen sensor FNR
and others. All these 'redox receptors' have a structure
designed to sense specific ROS, oxidants or other reactive
intermediates. These ancestral redox sensors can essen-
tially contribute to fast mechanisms designed to deal with
ROS and to make adjustments allowing the survival of the
bacteria (that is, to reset redox homeostasis). During evo-
lutionary development these simple bacterial sensors
have been replaced with more specifically designed pro-
teins, such as yeast thiol peroxidases (enzymes belonging
to the family of peroxyredoxins or GPXs), which contrib-
ute to H2O2 signalling (see Figure 10 for more details).
Redox sensors in higher eukaryotes
In higher eukaryotes redox regulation of transcription, as
well as of signalling elements like protein phosphatases,
relies on properties and strategies similar to those
described for bacteria or yeast (cysteine-based oxidation/
reduction cycles), which have been evolutionarily con-
served. Here we still see thiol peroxidases affecting H2O2-
dependent signalling, with some crucial differences since
PRXs and GPXs have been reported to be involved in the
modulation of signal pathways. Figure 11 illustrates estab-
lished examples of three different mechanisms by which
an increase in intracellular ROS may trigger transcription
of redox sensitive genes: redox reactions directly involving
either signalling components or transcription factors;
nuclear translocation of transcriptional regulators that are
maintained in an inactive form in another cellular com-
partment; and modulation of transcription by alterations
in the so-called 'redox buffers'. More details can be found
in the legend to Figure 11 and in [18,71-73].
The meaning of redox sensors and redox signalling in higher 
eukaryotes
In mammalian cells, ROS-specific responses such as those
regulated by p53, activator protein (AP)-1, nuclear factor
(NF)-κB, c-Myc, FOXO and other factors can be seen as
part of long-term differentiation programmes that inte-
grate ROS protection and multiple metabolic/adaptative
responses. Higher eukaryotes have developed strategies
that, by diverting the original defensive design of redox
signalling, use intracellular ROS produced within cells to
modulate several signalling pathways, such as those
downstream of growth factor receptors. Redox changes
and ROS signals may potentially simultaneously affect
different signalling pathways, modulating main meta-
bolic or adaptative responses of cells and playing a strate-
gic role in several physiological or pathophysiological
conditions, including many chronic diseases of clinical
relevance.
Chronic injury and liver fibrogenesis: the tissue, 
cellular and molecular scenario involving liver 
parenchyma as a paradigm to introduce the role 
of ROS and redox signalling
Liver tissue has a unique ability to respond to different
injuries leading to parenchymal damage, which may also
include damage to endothelial cells and sinusoids as well
as to other non-parenchymal cells. Following a single
acute injury, healing in the liver can be envisaged as a
highly coordinated and sequential process (the more rele-
vant steps are summarized in Figure 12) involving recruit-
ment of inflammatory cells and extracellular matrix
(ECM)-producing cells and compensatory hyperplasia of
hepatocytes, with the final goal of 'restitutio ad integrum'.
The response to acute liver injury may vary, as in fulmi-
nant acute liver failure and/or in the presence of specific
toxins or carcinogens, by involving a response also includ-
ing proliferation, plus differentiation, of bi-potent hepaticFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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progenitor cells (HPCs) located at the level of the ductules
of Hering (see [74] and references therein).
The scenario changes significantly in CLDs, which are typ-
ically characterized by persisting liver injury due to
chronic infection by hepatotropic viruses (mainly HCV
and HBV) as well as to autoimmune, metabolic, toxic or
drug-induced causes, with ethanol consumption repre-
senting either a major single cause of toxic chronic injury
or a very common additive one. As a result of these condi-
tions (more details are given in Figure 13), persistent
inflammatory reaction and chronic activation of the
wound healing response will occur, sustaining progres-
sion of fibrogenesis to the end-point of cirrhosis [74-83].
The dynamic motor of CLD progression is likely to be rep-
resented by fibrogenesis. Figure 14 briefly summarizes the
impressive 'numbers' that reveal the global clinical impact
of progressive fibrogenesis and indicates those features
that are likely to serve as major predictors of fibrosis pro-
gression in a CLD. An extensive review of liver fibrogene-
Relevant examples of redox sensors in prokariotic cells and yeast Figure 10
Relevant examples of redox sensors in prokariotic cells and yeast. In the case of redox sensors described in yeast, the follow-
ing can apply. The redox sensor Orp-1 of Saccharomyces cerevisiae (Oxidant receptor peroxidase-1, also known as Gpx3) is 
known to interact with hydrogen peroxide at Cys36, forming a -SOH group that, in turn, will lead to rearrangement (disulphide 
bonds) in the OxyR analogue Yap1 transcription factor and in the associated Ybp1 protein, leading ultimately to Yap1 nuclear 
translocation and Yap1-dependent gene activation [18,71]. Similar systems have also been described in Schizosaccharomyces 
pombe and a very similar mechanism has been described for PRX-Tpx1.
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sis and its progression to cirrhosis is beyond the scope of
this review and the interested reader can refer to several
reviews in the specific field [75-84]. Here only crucial tis-
sue, cellular and molecular concepts and mechanisms will
be mentioned.
Patterns of fibrosis progression in CLDs
Fibrosclerotic progression follows distinct patterns that
are intrinsically related to the aetiological cause of the
CLD and the topographic site of tissue injury, as well as to
the predominant pro-fibrogenic mechanism and the
involvement of populations of pro-fibrogenic myofibrob-
last-like cells of different origin (MFs). Four main patterns
Redox sensors, redox signalling and control of redox sensitive transcription in higher eukaryotes Figure 11
Redox sensors, redox signalling and control of redox sensitive transcription in higher eukaryotes. (a) Redox reactions involv-
ing transcription factors such as Ref1 (Redox-factor-1); Ref-1 is a ubiquitous reductase having cysteine residues (Cys65 and 
Cys94) that are believed to be critical for redox-dependent modification of several transcription factors, including AP-1 (activa-
tor protein-1), NF-κB (nuclear factor κB), p53, ATF/CREB (activating transcription factor/cAMP-response element-binding 
protein), and HIF-1α (hypoxia-inducible factor 1α). Ref-1 acts by reducing -SOH groups and/or oxidized cysteine residues or 
disulphide bonds present on transcription factors that, under these 'oxidized' conditions, have reduced or absent DNA-binding 
activity; the 'reduced' transcription factors then become able to bind their related sequences on DNA (shown here are the 
two examples Ref-1/p53 1 and Ref1/AP-1 2). (b) Nuclear translocation of transcriptional regulators that are maintained in an 
inactive form in another cellular compartment; a characteristic example is Nrf-2 (nuclear factor (erythroid-derived-2)-like-2), 
which is a transcriptional regulator able to bind to the so-called ARE (antioxidant responsive elements) regulatory sequences 
that are located on genes encoding a number of enzymes involved in detoxification, including those for glutathione S-trans-
ferases, NAD(P)H quinine oxidoreductase, the multidrug resistance-associated protein and cysteine-glutamate exchange trans-
porter, thus up-regulating their transcription. In this case, Nrf-2 is usually bound to KEAP-1 (Kelch-like ECH associated 
protein-1) receptor or sensor, a protein rich in cysteine residues that usually forms a complex with cullin-3 and Nrf-2 to target 
the latter for proteasomal degradation. Exposure to oxidative stress (oxidation of Cys151, Cys273 and Cys288 combined with 
other reactions, including a Cys-zinc redox centre) results in modification of KEAP-1, leading to arrest of Nrf-2 ubiquitylation, 
allowing Nrf-2 to detach from KEAP-1 and translocate into the nucleus. (c) Modulation of transcription by alterations in the 
so-called 'redox buffer'; this concept indicates simply that several transcription factors as well as DNA modifying enzymes are 
sensitive to the most relevant reduced/oxidized molecular redox pairs, such as GSH/GSSG, NADPH/NADP and NADH/NAD. 
Examples of this way of coupling redox status to transcription factors or chromatin modifying enzymes include proteins that 
regulate circadian rhythms (Clock, NPAS2 and BMAL1), the protein for transcriptional silencing related to lifespan, SIRT1, and 
the transcriptional repressor C-terminal-binding protein (CtBP).
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of fibrosis have been identified and are described in detail
in Figure 14.
Myofibroblast-like cells as pro-fibrogenic effectors in CLDs
MFs are pro-fibrogenic cells found in chronically injured
liver in either experimental or clinical conditions. They
are characterized by a positive stain for α-smooth muscle
actin (α-SMA). The origin of liver MFs has been a matter
of controversy for more than a decade but now there is
substantial agreement on the following major concepts
(summarized in Figure 15). First, three different pheno-
types of MFs have been identified in fibrotic/cirrhotic liv-
ers of human patients or in animal models, including
hepatic stellate cells (HSCs) that become activated or
HSC/MFs (in capillarised sinusoids), interface myofibrob-
lasts (MFs located at the interface between fibrotic septa
and the surrounding parenchyma) and portal/septal
myofibroblasts (MFs in the expanded portal areas or
within fibrotic septa) [85,86]. Second, liver MFs have
multiple origins, with most originating from HSCs;
indeed, most of our present knowledge comes from stud-
ies investigating this peculiar liver cell population, as
recently reviewed by Friedman [81]. HSCs are likely to
give rise to HSC/MFs and to most interface MFs; MFs can
also originate from portal fibroblasts, which are also able
to give rise to the phenotypically identical septal MFs. A
significant number of MFs can also originate, in chroni-
cally injured human [87] and murine livers [88,89], from
bone marrow-derived mesenchymal stem cells (MSCs),
suggesting caution when considering therapeutic proce-
Acute liver injury: when healing is a coordinated and sequential process Figure 12
Acute liver injury: when healing is a coordinated and sequential process. A standard acute liver injury leading to irreversible 
parenchymal damage is followed by recruitment in the injured site of resident (Kupffer cells) or peripheral blood-derived acti-
vated monocyte/macrophages, resulting in phagocytosis, and the release of growth factors, cytokines, chemokines and ROS. 
Healing proceeds with recruitment of ECM-producing cells (HSCs and/or portal fibroblasts) and, likely, also of endothelial pro-
genitor cells (EPCs): recruitment of these cells is essential to provide deposition of new ECM (basal membrane-like) and to 
form new sinusoids. Next, HSCs in excess will undergo apoptosis and the 'restitutio ad integrum' will require compensatory 
hyperplasia of hepatocytes that have survived the original injury as a response to a number of growth factors released by either 
inflammatory cells, endothelial cells or HSCs.
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dures involving autologous transplant of bone marrow-
derived stem cells [90]. Third, whatever the origin, all the
mentioned 'precursors' of ECM-producing cells in CLDs
are likely to undergo a similar process of activation and
trans-differentiation that leads to the peculiar MF-like
phenotype [82,90]; thus, the actual 'feeling' is that HSC/
MFs, and likely all activated MF-like cells, may share, from
a functional point of view, the ability to exhibit a number
of phenotypic responses [80,81,91] (summarized in Fig-
ure 15), including proliferation [76,81,83,92,93], synthe-
sis and remodelling of ECM and of mediators, migration,
contractility and the potential to undergo apoptosis
[80,81,91,94]. More details are given in the legend of Fig-
ure 15.
Major events, cells and mechanisms regulating liver 
fibrogenesis in CLDs
Several relevant events for fibrosclerotic progression of
CLDs may be considered relatively independent of the
specific aetiology, as detailed in Figure 13; in these condi-
Schematic representation of events involved in fibrosclerotic development of CLDs Figure 13
Schematic representation of events involved in fibrosclerotic development of CLDs. CLDs may involve different aetiological 
agents or conditions able to cause persisting parenchymal liver injury (1) and then hepatocyte (HC) cell death (either necrosis 
or apoptosis) (2). As a result, a persistent inflammatory reaction can occur (3), which may significantly affect the progression of 
the disease by either contributing to the perpetuation of injury (4) or 'creating' a growth factor, cytokine and mediator pattern 
favouring tissue repair and the activation of ECM-producing cells (5). This chronic scenario will lead to activation of myofibrob-
last-like cells that will contribute either to perpetuation of inflammation by releasing pro-inflammatory mediators (7) or to the 
wound healing response by excess and progressive accumulation of fibrillar (rich in collagen type I and III) extracellular matrix 
(ECM) components. If the aetiological agent or causal condition persists, the CLD can undergo a fibrosclerotic progression to 
cirrhosis and liver failure [74-81]. Cirrhosis in turn may be defined as an advanced end-stage of fibrosis, characterized by for-
mation of regenerative nodules of parenchyma surrounded and separated by fibrotic septa, a scenario that is intrinsically asso-
ciated with significant changes in hepatic angio-architecture [81-83].
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tions of persisting tissue injury, ROS and other related
mediators, released by damaged cells or activated inflam-
matory cells, are likely to play a relevant role. Along these
lines, it should be noted that, in chronic diseases, both
necrotic and apoptotic, as well as apoptosis-like, forms of
cell death have been reported to occur and have been
detected in the same tissue section [80,95,96] and that
Concepts and numbers Figure 14
Concepts and numbers. (a) The clinical impact of progressing fibrogenesis. (b) Predictors for fibrosis progression in CLDs. (c) 
Patterns of fibrosis progression in CLDs.
b)
  male gender
  age at infection (mainly for HCV)
  daily alcohol intake
  obesity and diabetes mellitus
  hepatic iron content
  individual factors leading to differences in:       - immune response vs infection agents and related auto-antigens
- drug metabolism
Bridging fibrosis, a pattern of ECM deposition and septa formation, seen mainly in the liver of patients with HBV or 
HCV chronic hepatitis, that results from portal-central bridging necrosis and lead mainly to the formation of portal-
central fibrotic septa, apparently bridging portal areas with the area of central vein. This pattern, typically associated 
with interface hepatitis, can lead also to the development of septa bridging portal areas (portal – portal septa) and of 
blind septa in the parenchyma. Fibrotic septa will also lead to obliteration of central veins and early changes in 
vascular architecture and connections with the portal system, favouring the development of portal hypertension. 
Chronic wound healing is the main pathogenetic mechanism driving this pattern of fibrosis progression and MFs
involved can be either derived from HSCs, portal fibroblasts or even from bone marrow stem cells (see later). ROS 
have also been described to concur to pathogenesis. 
Perisinusoidal/pericellular fibrosis. This pattern predominates in CLD having alcoholic aetiology (ASH or alcoholic 
steatohepatitis) or in those conditions of metabolic derangement progressing from non-alcoholic fatty liver disease 
(NAFLD) to non-alcoholic steatohepatitis (NASH). Here, excess deposition of ECM components in the space of Disse
leads to the characteristic “chicken-wire” pattern and is mainly due to HSC/MFs (MFs derived from activation of 
HSCs); moreover, generation of ROS and oxidative stress predominate as main pathogenic mechanism. 
Biliary fibrosis. This definition refers to a rather unique condition, usually seen in diseases affecting the biliary tree, in 
which there is a concomitant proliferation of reactive bile ductules and periductular MFs (here mainly derived from 
periportal fibroblasts) leading to formation of portal – portal septa that for long time do not affect significantly vascular 
connections with portal system. For this pattern, significant alterations in the interactions between epithelial cells (i.e., 
biliary epithelial cells or BEC) and mesenchymal cells have been proposed as relevant in the pathogenesis together 
again with ROS and oxidative stress. 
Centrilobular fibrosis. This pattern is typically recognized in patients affected by chronic heart failure in which a 
significant alteration of venous outflow is realized; fibrotic septa develop between central vein areas (central – central 
septa) and lead to the scenario often defined as of “reversed lobulation”.  
Numbers/Scenarios Concepts
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hepatocyte apoptosis represents an effective pro-fibro-
genic stimulus [97,98].
To complete the oversimplified scenario offered in Figure
13 (more details in [74,91,95]), the following concepts
should be recalled. First, in such a complex scenario sev-
eral other cellular 'actors' are likely to be involved; Figure
16 summarizes all the cells involved in CLDs, indicating
how they can contribute to fibrogenesis progression and,
for some of them, to the generation of ROS or related reac-
tive intermediates. Second, a major pathogenic role has to
be attributed to several soluble factors (produced by dif-
ferent kind of cells; Figure 16) that can regulate both the
state of activation of MFs and their phenotypic responses
Origin of MF-like cells and their activation in the scenario of a CLD Figure 15
Origin of MF-like cells and their activation in the scenario of a CLD. Myofibroblast-like cells (MFs) may originate, under CLD 
conditions, from either quiescent HSCs, portal fibroblasts or bone marrow-derived MSCs able to engraft the chronically 
injured liver. Whatever the origin, MFs are believed to be characterised by the following properties and phenotypic responses: 
(a) high proliferative attitude; (b) increased ability to synthesise ECM components, particularly collagen type I and III; (c) 
altered ability to express matrix metallo-proteinases (MMPs) and related tissue inhibitors (TIMPs), resulting in an altered ability 
to remodel ECM in excess; (d) increased ability to migrate in response to different stimuli, including truly chemotactic ones; 
(e) increased synthesis of growth factors and pro-inflammatory cytokines and chemokines [76], including pro-angiogenic 
cytokines [81,83,92,93], that may act as paracrine as well as autocrine mediators; (f) contractility in response to vasoactive 
compounds like NO, endothelins and others; (g) the potential to undergo apoptosis in case of removal of the aetiological 
agent (that is, successful therapy, alcohol withdrawal, and so on) or causative conditions [80,81,91], although fibrosis regression 
has been mainly observed in experimental models. Here it should be mentioned that although there is no doubt that fibrosis is, 
at least in principle, a potentially reversible process, a complete reversion of cirrhosis (particularly for human cirrhotic livers) 
has never been convincingly documented [84] and human HSC/MFs have been shown to possess a peculiar survival attitude 
both in vitro as well as in vivo that may indeed favour progression over reversion [94].
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The other cellular 'actors' in hepatic chronic wound healing: the roles of the different cell types, including those that may be  related to redox state and signaling Figure 16
The other cellular 'actors' in hepatic chronic wound healing: the roles of the different cell types, including those that may be 
related to redox state and signaling.
1) HEPATOCYTE (HC) - primary target for several agents/conditions able to induce cell injury and death 
- most of agents/conditions leading to HC injury are able to generate ROS, HNE, and 
other free radicals 
- damaged HC can release ROS and other reactive intermermediates in the 
surrounding microenvironment
- HC can also release IGF-1 and, under hypoxia, VEGF
- during chronic liver diseases, surviving HC can proliferate in an attempt to
repopulate injured liver 
- recruited Mc and resident KC become activated in conditions of chronic liver injury 
- Mc and KC can act by phagocytosis of cell debris & apoptotic bodies as well as 
APC
- on activation, they can generate and release: ROS and other reactive 
intermediates; several GFs, CKs & mediators, including PDGF, bFGF, TGF, TNF,
IL-1, PGs, etc; selected MMPs
2) MONONUCLEAR 
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KUPFFER CELLS (KC)
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IL-1, TGF, IGF-1, PGs, ETs, VEGF; NO and ROS
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ENDOTHELIAL CELLS 
(SEC)
- when recruited/activated at the site of injury they can release: PDGF, EGF, TGF,
TGF, TXAs, IGF-1
4) PLATELETS
- recruited to the liver under conditions of chronic liver injury induced by viruses
(HBV, HCV), chronic alcohol consumption, auto-immune conditions, etc.
- may contribute to perpetuation of liver injury
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as well as the responses of other cells involved; these fac-
tors include platelet-derived growth factor (PDGF), trans-
forming growth factor (TGF)β, connective tissue growth
factor (CTGF), endothelin-1 (ET-1), monocyte chemotac-
tic protein (MCP)-1, and tumour necrosis factor (TNF), to
name just a few. Third, several signalling pathways, tran-
scription factors and related transcriptional gene regula-
tion have been dissected and identified as involved in the
process of activation of HSCs or in mediating phenotypic
responses of MFs, and most of these (see next section) are
known to be redox-sensitive. Fourth, angiogenesis, pro-
angiogenic cytokines and expression of related receptors
are emerging as crucial factors potentially able to contrib-
ute actively to liver fibrogenesis [83,92,93]. Finally, oxida-
tive stress as well as increased generation of ROS, HNE,
NO and RNS have been unequivocally detected in all clin-
ical conditions and animal models of fibrogenic CLD;
moreover, administration of antioxidant agents in animal
models usually offers prevention ([35,36] and references
therein).
ROS and intracellular signalling cascades: redox 
sensitive molecular targets in signalling 
pathways likely to be involved in chronic wound 
healing
Signal transduction elicited by interaction of peptide fac-
tors (growth factors, cytokines, chemokines as well as
other ligands) with their respective receptors can be
enhanced or modulated by intracellular ROS generation.
Indeed, peptide ligands also trigger activation of NOX but
the positive feedback on signal transduction can also be
elicited whatever the source of ROS, including ROS pro-
duced by mitochondria and other intracellular sources or
entering the cell from the extracellular environment. The
latter can include H2O2, which has a rather long half-life,
a relatively low reactivity and an intrinsic ability to cross
biological membranes. The literature concerning redox
sensitive signalling pathways is now impressive (for more
details, see [14,15,17,49]) and here we present the most
established concepts that may have a major role in
chronic wound healing.
ROS and receptor-mediated signalling pathways
ROS have been shown to mediate a positive feedback on
signal transduction elicited by, for example, PDGF, epi-
dermal growth factor or nerve growth factor; this usually
reinforces the receptor tyrosine kinases (RTKs) (Figure 17)
and involves p21Ras and Rac, leading to activation of a
subunit of non-phagocytic NOX, likely a gp91phox ana-
logue. TGFβ1, which operates by binding receptor serine/
threonine kinase and involves Smads and Src kinases, as
well as other relevant ligands in a scenario of chronic
wound healing (as in CLDs), including interleukin (IL)-1,
TNF, angiotensin II (Ang II), thrombin and insulin, have
also been described to lead to activation of a NOX in non-
phagocytic cells to generate O2
￿-, which will then sponta-
neously or enzymatically dismutate into H2O2. The reader
may then envisage a scenario in which non-phagocytic
cells involved in chronic wound healing receive signals
from the extracellular milieu, such as those derived from
peptide factors binding their receptors or extracellularly
generated ROS or other oxidants, and then face an
increase in intracellular ROS that affects signalling path-
ways by one or, more likely, two or more of the following
mechanisms.
ROS can enhance signalling pathways by inhibiting protein tyrosine 
phosphatases
Protein tyrosine phosphatases (PTPs) can be considered
as negative regulators of RTK-mediated signalling, switch-
ing off the activated receptor by means of dephosphoryla-
tion [49,99-101]. However, ligand-induced activation of
RTKs can lead (as for PDGF signalling; Figure 17) to phos-
phoinositide 3-kinase (PI3K)-mediated activation of Rac
that, in turn, is able to switch on ROS generation by NOX
[49,99]. ROS such as H2O2 can act on a redox-sensitive
cysteine residue with a low pKa in the active site of PTPs (a
similar condition has been described also for p21Ras, AP-
1, NF-κB and hypoxia-inducible factor (HIF)-1) by oxidiz-
ing the -SH group of the active PTP. Depending on ROS
levels (Figure 17), this may result in reversible as well as
irreversible inactivation of PTPs, reinforcing downstream
RTK signalling for variable durations. This scheme has
been described also for radiation, exposure to metals,
alkylating agents and environmental oxidants, and condi-
tions that may even activate RTKs in a ligand-independent
manner ” 'RTK trans-activation' [102]. Changes in intrac-
ellular thiol/disulfide redox state may also affect the sys-
tem since the relative, or time-limited, depletion of
reducing agents may prevent reversion of oxidized/inac-
tive PTPs to the reduced/active state.
ROS can activate protein kinases as well as MAPK cascades
Cytoplasm protein kinases can respond to very high levels
(1 mM) of H2O2 by enhancing their activity, as shown in
pioneeristic studies [14,15]. Whether these high concen-
trations of ROS may be reached in a biological environ-
ment is still controversial. If one refers to more realistic
studies, few molecular targets and pathways have been
identified to be activated by mild oxidizing conditions or
by mild shifts in the intracellular thiol/disulfide redox
state, including signalling components of the Src family of
protein tyrosine kinases (p59fyn and p56lck), JAK2, c-Jun
amino-terminal kinases (JNKs), p38MAPK and, in some
cells, ERK1/2. A peculiar mechanism is the one disclosed
in studies designed to analyze ASK-1 (apoptosis signal-
ling-regulating kinase 1) activation, which, in turn, leads
to activation of MKK3/6, MKK4/MKK7 and then JNKs and
p38MAPK, finally leading to phosphorylation of ATF-2, c-
Jun and p53. Elegant studies have shown that ASK-1 isFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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usually associated with a Trx protein that binds to the
amino-terminal domain of ASK-1, inhibiting its kinase
activity. If ROS induce Trx dimerization and dissociation
from ASK-1, this is followed by multimerization of ASK-1,
activation of its kinase activity and then of the down-
stream signalling, leading to activation of JNKs and
p38MAPK [103,104].
Another interesting example of redox sensitivity is that of
the serine/threonine kinase protein kinase Cα (PKC-α)
[14,15]: this and other PKC isoforms are usually activated
by diacylglycerol or phorbol esters, for which PKC has a
binding site in an evolutionarily conserved cysteine-rich
region. These PKC isoforms can be activated by ROS like
H2O2 in a way that involves tyrosine phosphorylation in
the catalytic domain. Interestingly, vitamin E has been
described to inhibit the activity and translocation of PKC
to the membrane and to be able to down-regulate some
PKC-dependent responses (that is, proliferation) in target
cells like smooth muscle cells; intriguingly, data on mod-
ulatory effects by vitamin E have been extended to other
components of the signalling machinery, suggesting that
only some of these effects may depend on the antioxidant
activity of the vitamin [105].
ROS and oxidative stress can activate defined transcription factors
Several transcription factors can be considered as redox
sensitive but the two best characterized examples are NF-
ROS may modulate receptor tyrosine kinase (RTK) signalling by regulating protein tyrosine phosphatases (PTPs) redox state Figure 17
ROS may modulate receptor tyrosine kinase (RTK) signalling by regulating protein tyrosine phosphatases (PTPs) redox state. 
When a peptide ligand such as PDGF binds to its receptor RTK on the surface of a non-phagocytic cell (for example HSC/MFs), 
the signal can involve activation of PI3K and Rac, which in turn will result in activation of membrane NOX and generation of 
ROS. Within the cell ROS, such as H2O2, may act on a redox-sensitive cysteine residue in the active site of PTPs and transform 
the -SH group into the oxidized ” SOH group (sulphenic acid), thus reversibly inactivating PTPs. Under physiological conditions 
and with low levels of ROS this change is rapidly reverted by reducing agents, with this transient redox inhibition of PTPs hav-
ing a relevant role in RTK signalling. However, in conditions in which intracellular ROS are significantly increased, this may lead 
to more oxidation and then to irreversible changes, with formation at the level of the sensitive cysteine residues of sulphinic 
and sulphonic acid. These oxidized forms of PTPs are inactive and this will result in long-lasting blocking of PTP-dependent 
receptor dephosphorylation, allowing a positive reinforcement of RTK downstream signal transduction. The intracellular thiol/
disulfide balance potentially plays a relevant role here: cellular levels of GSH or other reducing agents, for example, may oper-
ate to revert the sulphenic acid group in the active site of PTP to the thiolate anion, converting PTP back to the active state.
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κB and AP-1. NF-κB is a transcription factor shown to
respond to oxidative stress [106] and it is known to be
involved in inflammatory reactions, in the control of cell
growth and the balance between survival and apoptosis
[107] and, possibly, necrotic cell death [108] (see below).
NF-κB, a definition that, in mammalian cells, includes c-
Rel, RelA (p65), RelB, NF-κB1/p50 and NF-κB2/p52 pro-
teins, which all recognise DNA sequences called κB sites
[107,109,110], is also involved in maintaining mitochon-
drial integrity and in regulating antioxidant activity
[107,110]. The redox-dependence of NF-κB relies on dif-
ferent mechanisms of activation that, depending on the
specific target cell, may involve either an atypical phos-
phorylation of the Tyr42 residue of IκBα by the kinase Syk
(thus, independently of IκB kinase (IKK)) or a more con-
ventional H2O2-dependent activation through the classic
IKK-dependent pathway [110], the latter being activated
also by HOCl, singlet oxygen and peroxynitrite.
Pertinent to this review, a general model is emerging sug-
gesting that all cytokines leading to NF-κB activation are
likely to cause intracellular generation of ROS that are
then responsible for IKK activation and IκBα degradation,
with IL-1, TNF and LPS being the. best characterized
examples (Figure 18). The concept here is again simple:
ROS, produced intracellularly as a part of the response
induced by inflammatory cytokines, contribute to rein-
force the signal. Figure 19 oversimplifies the concepts
described above (in the 'Principles of redox homeostasis'
and 'Redox sensors and the basis of redox-dependent tran-
scriptional regulation' sections) by proposing an intuitive
model that relates the levels of ROS and oxidative stress to
the overall response and even fate of the target cells.
Within the same scenario one can also easily include AP-
1, a dimeric (homo- or heterodimer) transcription factor
typically formed from c-Jun and c-Fos and involved in sev-
eral physiological and pathophysiological processes. Acti-
vation of AP-1 occurs in the presence of low levels of ROS
(mainly H2O2), IL-1, UV light, and γ-irradiation. Two
mechanisms may lead to redox-dependent activation of
AP-1: oxidative activation of JNKs that, in turn, phospho-
rylate Ser63 and Ser73 of the amino-terminal transactiva-
tion domain of c-Jun, a domain that is essential for
functional activation [104]; and a mild shift in the redox
state by different oxidants or ROS [14,15].
A cautionary note has to be added: one should keep in
mind that the DNA-binding activity of most transcription
factors is redox sensitive in the opposite way. It has been
shown that the binding of transcription factors to a DNA
regulatory sequence requires reducing conditions because
transcription factors must expose positively charged
amino acid residues in their binding sites in order to be
able to bind target DNA sequences (usually highly acidic
and negatively charged). This introduces an apparent par-
adox: the binding site of a transcription factor presents
redox-sensitive amino acids (cysteine, arginine) and, as is
the case for NF-κB, oxidation of these critical residues may
prevent its DNA-binding activity. This note is to underline
that even in physiological conditions, the final response
to redox changes relies on a delicate balance between pro-
oxidant conditions needed to reinforce the signal and
reducing conditions needed for the same signal (that is,
the transcription factor) to be efficiently delivered in order
to obtain the response. Pathophysiological conditions
(Figures 9 and 19) can easily interfere with such a delicate
balance by shifting redox homeostasis to a 'quasi-stable'
but deregulated redox state.
ROS and oxidative stress in relation to CLD 
aetiology
In addition to the general mechanisms able to sustain
increased generation of ROS and other reactive mediators
that are common to all conditions of human and experi-
mental CLDs (that is, cell injury and death, chronic hepa-
titis, responses to growth factors, cyto- and chemokines,
and so on), one should also consider the intrinsic contri-
bution of the specific aetiology of a CLD. This is relevant
when the primary aetiology is represented by chronic eth-
anol consumption, a disturbance of iron homeostasis or
metabolic imbalances like those occurring in non-alco-
holic fatty liver disease (NAFLD) and non-alcoholic stea-
tohepatitis (NASH). Clinical observations have clearly
established that all these three very common conditions,
as independent factors, may significantly affect and accel-
erate fibrogenic progression of any CLD towards cirrhosis.
Iron and its role in fibrogenic CLDs
Iron in its ferrous (Fe2+) or ferric (Fe3+) forms is critical for
the life of all aerobic organisms, being included in haemo-
proteins like haemoglobin and myoglobin, metallopro-
teins, cytochromes and redox-dependent enzymes
involved in oxygen and electron transport as well as in
several other reactions, including oxygen sensing, NO
sensing, DNA synthesis and transcriptional regulation.
Major achievements in the understanding of hereditary
hemocromatosis (HH) have disclosed in a detailed way
[111,112] crucial molecular and cellular mechanisms
responsible for the control of iron homeostasis. Iron lev-
els are carefully controlled in terms of adsorption, stores,
plasma levels and transferrin saturation, whereas major
physiological pathways for its excretion are lacking in
higher organisms. The literature suggests that increased
levels of hepatic iron (the liver being the most relevant site
of storage) can significantly contribute to fibrogenic pro-
gression of a CLD.
Whatever the reason for increased hepatic iron levels, Fig-
ure 20 offers a simplified and 'iron-centric' view of howFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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the metal may exacerbate oxidative stress and its conse-
quences, which may range from redox-mediated cytotox-
icity to ROS, radical and non-radical intermediate-related
pro-inflammatory and pro-fibrogenic action (for more
details, see [113]). Figure 20 (more details in [112-119])
also offers additional information detailing the role of
excess iron in relation to HH, chronic HCV infection,
NAFLD/NASH or alcoholic liver disease (ALD).
If one comes back to the central point (that is, how iron
may contribute to fibrogenesis and CLD progression), sev-
eral hypothesis have been proposed in which the pro-oxi-
dant role of the metal ion remains prominent. The
following concepts may be relevant: first, increased oxida-
tive stress and lipid peroxidation have been detected in
association with all major conditions of hepatic iron over-
load [35,113]; second, in animal models evidence sug-
gests that antioxidant supplementation is able to
significantly prevent both iron-dependent chronic liver
injury and excess ECM deposition [35,120,121]; and
third, iron overload may induce cytotoxicity that prima-
rily depends on the ability to generate oxidative stress and
operates by inducing mainly mitochondrial damage
(including damage to mitochondrial DNA) and destabili-
zation of lysosomal membranes [122-124].
Two examples of ROS involvement in cytokine-dependent NF-κB activation Figure 18
Two examples of ROS involvement in cytokine-dependent NF-κB activation. (a) NF-κB activation by IL-1β. In some cells IL-1β 
induces MyD88-dependent endocytosis of IL-R1; during endocytosis Rac1 recruits NOX2 in the endosomal compartment. 
NOX2 activation generates superoxide that spontaneously dismutates into H2O2, which then diffuses in the cytoplasm and 
triggers TRAF6 association with the ligand-receptor complex on the endosome, leading finally to NF-κB activation. (b) NF-κB 
activation by LPS. NF-κB activation by LPS through TLR4 activation involves Myd88 recruitment, which links TLR-4 activation 
to IRAK and TRAF6, mediating NF-κB activation. The involvement of ROS is consequent to direct interaction, followed by the 
Rac1-mediated activation of TLR-4 by NOX4 (or another NOX isoform, depending on the target cells). At present it is uncer-
tain whether H2O2 operates (as for IL-1) by triggering activation of TRAF6.
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Another concept should be recalled: intracellular levels of
iron are usually carefully controlled (as in hepatocytes or
macrophages) by means of iron binding to cytoplasmic
Iron regulatory proteins (IRP-1 and IRP-2) and the expres-
sion of genes involved in iron homeostasis through the
binding of IRPs to Iron responsive element (IRE)
sequences, including those for transferrin receptor (TfR)
and ferritin (Ft). An uncontrolled rise in intracellular iron
may lead to the formation of a low molecular weight pool
of iron potentially able to convert O2
￿- and H2O2 into
highly reactive ￿OH radicals or ferryl ions. IRPs may
indeed represent a target for ROS and RNS, possibly as
part of a more general scheme designed to protect the
intracellular environment from oxidative stress [125]. IRP
inactivation should, by down-regulating TfR expression
and up-regulating Ft, decrease the intracellular labile iron
pool, thus preventing amplification of iron-mediated oxi-
dative damage. We do not know whether these regulatory
mechanisms may be altered in CLDs, although it has been
proposed that inactivation of IRP-2 (which is usually
highly expressed in macrophages) by RNS may help to
explain iron sequestration patterns of macrophages
detected in tissues undergoing inflammation [125].
Copper is another transition metal acting as an excellent
pro-oxidant catalyst that may contribute to enhance oxi-
dative stress in Wilson's disease (WD), the human disease
in which hepatic copper overload can occur. WD is an
autosomal recessive disease caused by mutations in the
gene encoding the copper-transporting P-type ATPase,
ATP7B, required for copper biliary excretion [126,127]. As
for iron overload, copper overload has also been
described to cause hepatic oxidative stress, leading to
hepatocyte injury and subcellular damage to several struc-
tures [128], although other mechanisms, either oxidative
or non-oxidative, may offer significant contributions
[35,36,129].
Oversimplified scheme of responses induced by increased intracellular levels of ROS Figure 19
Oversimplified scheme of responses induced by increased intracellular levels of ROS.
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Figure 20 (see legend on next page)
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Chronic ethanol consumption and metabolism: induction 
of oxidative stress and related events
Chronic ethanol consumption can lead to ALD, which
encompasses a large spectrum of pathological liver
changes, ranging from simple fatty liver with minimal
injury to alcoholic steatohepatitis (ASH) and, in more
advanced stages, fibrogenic progression to cirrhosis. Pro-
gression of ALD is now considered a multifactorial proc-
ess involving nutritional, environmental and genetic
factors [130], and ethanol consumption also represents
one of the major host-related factors able to accelerate
progression of fibrosis towards cirrhosis in chronic HCV
patients [131,132] and, possibly, in patients affected by
CLDs with a different aetiology. The role of ROS and oxi-
dative stress in the pathogenesis of ethanol-induced liver
injury has been extensively investigated [133-136]. Here
the following relevant concepts are recalled. First, experi-
mental and clinical data indicate that oxidative stress and
lipid peroxidation are involved, with antioxidants and
free radical scavengers being able, at least in animal mod-
els, to afford prevention [135]. Second, ethanol-related
ROS can be produced by the mitochondria respiratory
chain, ethanol metabolizing (and ethanol-inducible)
cytochrome P450 2E1 (CYP2E1) in hepatocytes, but not
in HSCs [137], and NOXs of activated Kupffer cells or
infiltrating neutrophils [133-135]; NO produced by NO-
synthase of Kupffer cells and other RNS has also been
shown to contribute to ethanol-dependent hepatic injury
[135,136]. The CYP2E1 isoform can also lead to genera-
tion of the ethanol-derived hydroxyethyl radical. Third,
ethanol-induced oxidative stress is likely to contribute to
liver steatosis found in alcoholics [138] by causing an
impairment in either mitochondrial lipid oxidation [139]
or lipoprotein secretions, the latter being related to
enhanced degradation of ApoB100 [140] and/or oxidative
alteration of lipoprotein glycosilation in Golgi apparatus
[135]. Fourth, CYP-2E1 generated ROS and formation of
protein adducts by lipid peroxidation products may affect
proteasomal degradation leading to cytoplasmic aggre-
gates of cytokeratins 8 and 18, leading to the formation of
Mallory's bodies [141]. More features of ethanol-induced
oxidative stress are presented below (see the sections 'Eth-
Increased levels of iron can contribute to increased generation of ROS and other radical or non-radical intermediates, resulting  in a potentiation of cytotoxic, pro-inflammatory or pro-fibrogenic consequences Figure 20 (see previous page)
Increased levels of iron can contribute to increased generation of ROS and other radical or non-radical intermediates, resulting 
in a potentiation of cytotoxic, pro-inflammatory or pro-fibrogenic consequences. The role of iron in CLD progression. Hered-
itary hemochromatosis (HH) is a long-lasting disease in which hepatic iron levels increase progressively over a long period dur-
ing which no or relatively modest inflammation and injury can be detected; when hepatic levels of iron increase to over 60 
mmol/g dry weight, HSCs become activated and fibrogenesis becomes significant [113], although this transition (from non-
fibrotic to fibrotic and then later cirrhotic) is not yet completely clear and other risk factors (ethanol consumption and ALD, 
chronic infection by HCV, concomitant metabolic conditions leading to NAFLD) are likely to be involved. However, with 
regard to patients with chronic HCV infection, it has been proposed that mutations in the hereditary hemochromatosis HFE 
gene may be responsible not only for derangement of iron homeostasis and HH, but may also worsen or accelerate the course 
of CLD by eliciting a turn-over of redox active iron in both the liver and plasma; in other words, the hypothesis is that HFE 
mutations may additionally result in increased intracellular production of ROS and free radicals taking place in hepatocytes or, 
also on the basis of recent knowledge on the role of hepcidin (see the section 'ROS-dependent sustained activation of JNK: a 
common step in oxidative stress-dependent cell death') and the iron transporter ferroportin, may affect the ability of Kupffer 
cells to handle and retain iron [112,114,115]. Chronic HCV infection. In addition to what has been reported for HH, it should 
be recalled that non-hereditary (that is, secondary) increased hepatic iron levels have been shown to represent a significant 
determinant for both the severity and progression rate of CLD associated with chronic HCV infection. Along these lines, dif-
ferent laboratories have shown a correlation between liver iron levels and HSC activation as well as fibrosis progression 
[114,115], which can be significantly prevented by phlebotomy. It should be noted (reviewed in [113]), however, that other 
researchers did not find evidence for such a correlation. NAFLD and NASH. With regard to NAFLD, current evidence sug-
gests that metabolic disturbances leading to steatosis (as associated with obese or overweight patients and, usually, with the 
so-called metabolic syndrome, often also including diabetes and insulin resistance) are likely to represent the 'first hit'. In order 
for NAFLD to progress to non-alcoholic steatohepatitis or NASH a 'second hit' (see later) is believed to be necessary and usu-
ally identified as occurrence of oxidative stress. Along these lines, iron is a rather obvious candidate because of its well known 
role as an ideal metal catalyst for the generation of ROS and other free-radical or non-radical intermediates. Alcoholic liver dis-
ease (ALD). Homologous considerations (that is, the role of hepatic iron levels) may be advanced for ALD and may help to 
explain, at least in part, why only approximately 30% of patients with high levels of chronic alcohol consumption are likely to 
develop cirrhosis over time. As recently reviewed [113], there are several reasons to believe that iron is a serious and, likely, 
independent candidate factor able to contribute to progression of ALD to cirrhosis. For example, in the pre-cirrhotic stage, 
approximately 30% of ALD patients show an elevated hepatic iron index, but when the ALD progresses to cirrhosis the per-
centage of ALD patients having iron overload rises up to 60%. Interestingly, it was recently suggested that ethanol consumption 
is able to alter IL-6-dependent expression of hepcidin, a condition resulting in enhanced absorption of iron and hepatic sidero-
sis [118]. Other mechanisms that may enhance iron hepatic levels have been recently reviewed by Brittenham [119].Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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anol-related redox mechanisms leading to mitochondrial
damage and hepatocyte apoptosis', 'Redox mechanisms
and chronic inflammatory response in CLDs', 'Redox
mechanisms in liver fibrogenesis: pro-fibrogenic cells as a
functional target' and 'Redox mechanisms in immune
reactions associated with CLDs: fuel for chronic inflam-
mation and fibrogenic progression').
ROS and oxidative stress-related reactive intermediates in 
NAFLD and NASH: their generation and role in causing 
steatosis
The term NAFLD refers to a wide spectrum of disorders
having in common hepatic steatosis as a hallmark but also
encompassing NASH, advanced liver fibrosis and cirrho-
sis. NAFLD is actually recognized as a major cause of liver-
related morbidity and mortality, with a very high preva-
lence in Europe, USA and, more generally, in western
countries (reviewed in [142-145]).
The traditional 'two-hit theory' proposed by Day and
James [146] around ten years ago, which is still widely
accepted [142-145], is summarized in the scheme pre-
sented in Figure 21, which also provides more details on
mechanisms leading to increased circulating and hepatic
levels of free fatty acids (FFAs), the ultimate cause of stea-
tosis. There is consensus concerning the fact that long-
term injury from hepatocyte triglyceride storage is respon-
sible for the development of oxidative stress and, thus, sig-
nificant intracellular generation of related reactive
intermediates, with oxidative stress (detected in all clini-
cal and experimental conditions of NAFLD/NASH [147-
151]) representing the 'second hit', potentially favouring
NAFLD progression. Along these lines, impairment of
mitochondrial β-oxidation can lead to accumulation of
FFAs in hepatocytes and FFAs are substrates (ω-oxidation)
and inducers of cytochrome P450 isoforms CYP2E1 and
CYP4A. Both isoforms (overexpressed in human and ani-
mal NASH) can generate ROS that, in turn, can elicit lipid
peroxidation, a common hallmark of NASH [152-154]. In
addition, ROS may also be generated as a consequence of
increased FFA oxidation in peroxisomes (β-oxidation) by
Acyl-CoA oxidase.
Other mitochondrial dysfunctions occur in NASH
patients, some possibly due to up-regulation of uncou-
pling protein-2 (UCP-2) or representing the consequence
of an oxidative stress-dependent derangement of mito-
chondrial membranes and/or the respiratory chain that
may result in an increased release of ROS from mitochon-
dria. The role of UCP-2 is still controversial and has
recently been critically reviewed [155].
Oxidative stress and related reactive intermediates may
contribute, as proposed for ethanol, to the genesis of stea-
tosis by negatively affecting secretion of lipoproteins
(either by enhancing degradation of Apo-B100 or by
affecting lipoprotein glycosylation in the Golgi apparatus)
[135,140] or even by interfering with the regulation of
lipid synthesis by the sterol regulatory element binding
protein 1 (SREBP-1) or the peroxisome proliferator-acti-
vated receptor α (PPAR- α) [156]. Moreover, ROS have
been proposed to contribute to insulin resistance (IR)
itself: activation of stress-activated protein kinases by ROS
can lead to impairment of the correct transduction of
insulin-mediated signals through the induction of serine
and threonine phosphorylation of IRS-1 (insulin receptor
substrate-1) and the concomitant down-regulation of IRS-
1 tyrosine phosphorylation [157,158]. This has been con-
firmed by studies performed in hepatocytes overexpress-
ing CYP2E1 [159].
Finally, the pivotal role of ROS in NAFLD progression has
been shown by Xu et al. [160], who, in an elegant study
(commentary in [161]), described the key role of the Nrf-
1 gene, which is known to be involved in mediating acti-
vation of the oxidative stress-response. When using a
mouse model of selective hepatic deletion of the Nrf-1
gene, the liver of these animals developed progressively all
the characteristic features found in the progression of
human NAFLD, including steatosis, apoptosis, necrosis,
hepatitis, fibrosis and even liver cancer.
Chronic HCV infection and oxidative stress
The occurrence of oxidative stress is a common finding in
human patients affected by chronic HCV infection
(reviewed in [162]) and is likely to rely mostly on the
actual conditions of persisting liver injury and chronic
inflammation. However, experimental studies have pro-
posed that HCV core protein may induce mitochondrial
injury in hepatocytes, leading to increased generation of
ROS [163,164]. Mice overexpressing HCV core protein
showed alterations of redox homeostasis in the absence of
significant inflammation and were more susceptible to
the hepatotoxin CCl4 [163]. Moreover, overexpression of
viral proteins in these transgenic mice was found to be
associated with the development of steatosis and hepato-
cellular carcinoma, two common features of chronic HCV
infection in humans [165].
Other researchers have provided similar evidence for the
HCV non-structural protein 5A (NS5A), which has been
shown to associate with the membranes of endoplasmic
reticulum (ER) and increase generation of ROS and activa-
tion of NF-κB and STAT-3 [166] as well as of JNKs and p38
MAPK [167]. NS5A-mediated activation of NF-κB seems
to operate through tyrosine phosphorylation of IkBα and
its degradation by calpain protease [168]. Thus, HCV by
itself may contribute to elicit a state of oxidative and nit-
rosative stress in affected patients and the following major
concepts, as recently reviewed [169], should be outlined.Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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First, only some HCV-related proteins, such as NS5A, NS3
and HCV core protein, are likely to play roles in mediating
redox perturbations, which can include increased genera-
tion of both ROS and RNS, iNOS and COX-2 (NS5A and
C). Second, significant alterations of redox state may help
to explain synergistic effects of HCV and alcohol on the
progression of disease. Lastly, ROS and ethanol consump-
tion may influence HCV replication and affect the out-
come of interferon therapy.
Recently, another concept has been introduced by a study
performed on transgenic mice expressing the HCV poly-
protein: HCV-induced excess generation of ROS causes
down-regulation of hepcidin synthesis through inhibition
of the DNA binding activity of C/EBPα [170], an event
The two hit theory of NAFLD progression Figure 21
The two hit theory of NAFLD progression. Current literature indicates that the crucial derangement in NAFLD is represented 
by insulin resistance (IR), which is a key feature of the metabolic syndrome, a clinical entity that also includes type 2 diabetes 
mellitus, hypertrigliceridemia, hypertension, a decreased level of high-density lipoprotein and obesity. Indeed, as suggested by 
several authors, steatosis may simply represent the hepatic manifestation of the metabolic syndrome ([143,144] and references 
therein). The first hit is a metabolic one dominated by IR, with NAFLD being associated with both hepatic and adipose tissue IR 
as well as reduced insulin sensitivity of the whole human body [143,144,146]. This can lead from one side to 1) a significant 
reduction of glucose disposal and to a lack of suppression of hepatic glucose production as well as 2) a defect of disposal of free 
fatty acids (FFAs) at the adipocyte level (and skeletal muscle) that, in turn, 3) will open the way to high circulating levels of FFAs 
(and hypertrigliceridemia) coming from either subcutaneous and visceral fat, which will cause a persistent excess delivery of 
FFAs to the liver, the ultimate cause of liver steatosis [142-146]. Molecular details on how the excess load of FFAs to hepato-
cytes can lead to steatosis can be found in more specialized reviews [142,143], with increased de novo synthesis of fatty acids 
and triglycerides as well as both impaired oxidation (mitochondrial plus peroxisomal) and impaired efflux of fatty acids (by 
reduced synthesis of Apo-B100 or transport of VLDL particles) being the candidate responsible processes.
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able to increase iron transport from duodenum and iron
release from macrophages, which lead potentially to iron
overload and related consequences.
Chronic cholestatic diseases and oxidative stress
The pattern of fibrosis in diseases of the biliary tract is
peculiar and involves either significant alterations in the
interactions between cholangiocytes and mesenchymal
cells as well as generation of ROS and occurrence of oxi-
dative stress. In adults and children, chronic cholestasis is
usually the consequence of cholangiopathies due to
autoimmunity, infectious or toxic agents, ischemia or
genetically transmitted defects. All these cholangiopathies
share features such as cholestasis and cholangiocyte loss
associated with cholangiocyte proliferation and a variable
degree of portal and periportal inflammation and fibrosis
[171,172]; relevant is the 'cross-talk' between cholangi-
ocytes, portal MFs and/or HSCs, first demonstrated for
PDGF-BB and PDGF-β R [173], with cholangiocytes being
able to secrete IL-6, TNF, IL-8 and MCP-1 as well as PDGF,
ET-1, TGFβ2 and CTGF (reviewed in [171]).
Oxidative stress and lipid peroxidation have been
detected in the most relevant clinical conditions, includ-
ing primary biliary cirrhosis and the bile duct-ligation
model in the rat [174-178], with antioxidant providing a
significant degree of protection in animal models
(reviewed in [35,36]). Generation of ROS, induction of
oxidative stress and lipid peroxidation may represent the
consequences of activation of inflammatory cells, as in the
bile duct ligation (BDL) model [174], but ROS generation
may even follow a direct effect of hydrophobic and cyto-
toxic bile acids on hepatocyte's mitochondria, thus medi-
ating hepatocyte necrotic cell death and/or apoptosis
[128,179-182]. Recently, it has been suggested that intra-
cellular generation of ROS may also mediate cholangi-
ocyte apoptosis found in primary biliary cirrhosis [178].
Oxidative stress and genetic polymorphisms
Genetic polymorphisms may have a significant role in
fibrotic progression of CLDs, as suggested by the broad
spectrum of manifestations or responses that individual
patients offer to the same aetiological agent or condition.
Bataller and coworkers [183] have delineated a list of can-
didate genes involved and, not surprisingly, most, if not
all, of the 'suspected' polymorphisms concern factors or
enzymes that are known to be directly or indirectly either
redox-sensitive or involved in the generation of ROS or
other relevant reactive intermediates. The actual list
includes genes encoding cytochrome P450 isoform
CYP2E1, alcohol-dehydrogenases (ADHs), and Mn-SOD,
as well as a number of cytokines, including TGFβ1 and
TNFα.
Redox mechanisms in the induction of cell death 
in CLDs: much more than a dose-dependent 
process
Oxidative stress as an event able to induce cell death
Persisting liver injury and hepatocyte loss are common in
CLDs and oxidative stress is likely to play a relevant role
in inducing both necrotic as well as apoptotic cell death
[136,184-187]. Severe oxidative stress, able to signifi-
cantly damage any relevant biological macromolecule
and cellular structure, is an obvious candidate to induce
necrosis and may represent the outcome of severe inflam-
matory response following acute liver injury, with acti-
vated Kupffer cells, neutrophils or recruited mononuclear
cells from peripheral blood being the 'effectors' of
increased generation of reactive species. High levels of
intracellular oxidative stress may also be reached within
hepatocytes damaged by specific toxins (for example,
CCl4 and acetaminophen) or aetiologies (for example,
high levels of transition metal ions) or because of individ-
ual differences, including induction of peculiar cyto-
chrome P450 isoforms (such as CYP2E1 in ASH/ALD or
NASH), antioxidant status or even genetic polymor-
phisms.
In the scenario of a chronic inflammatory and fibrogenic
disease, the first point to be discussed is the following:
what do we mean, in terms of concentrations, by 'high lev-
els of oxidative stress'? The literature offers the following
considerations: reliable analytical (that is, quantitative)
data on steady state concentrations of ROS as well as of
other critical reactive intermediates are lacking for human
liver of patients affected by a CLD; and the best data come
from analyses performed on livers of animals undergoing
experimental models of acute liver injury. In the liver of
mice treated with acetaminophen, a model of severe and
oxidative stress-dependent acute liver injury and failure,
sophisticated techniques have detected a total concentra-
tion of approx 0.25 μM ROS, with H2O2 detected at levels
of 0.15 μM [188]; in the CCl4 model of oxidative stress-
related acute liver injury, intrahepatic levels of HNE
reached maximal values around 10 μM [189].
Data on acute liver injury should imply that during CLDs
tissue levels of ROS and other mediators are likely to be
lower; this has been shown for HNE levels, which ranged
from 1”3 μM in chronic CCl4  treatment and BDL
(reviewed in [35,36]). Although several researchers have
the feeling that in some conditions (that is, the environ-
ment of biological membranes within the cell, the site of
active inflammation, the concomitance of more 'pro-oxi-
dant events') ROS may locally reach levels higher then
those reported in [188], these data suggest caution when
interpreting results obtained in vitro by exposing either
suspensions of freshly isolated cells or cultured cells to
unrealistic concentrations of ROS or HNE, such as in theFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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range 0.1”1.0 mM. The problem of the 'steady state' con-
centration of reactive intermediates is not academic: reac-
tive intermediates of oxidative stress can induce necrotic
cell death, caspase-dependent apoptosis [184-186] or
other intermediate forms, including apoptosis-like or
necrosis-like cell death [96], even in the presence of the
same pro-oxidant agent or condition [179-182,190,191].
This is relevant in the parenchymal chronic 'battlefield':
whatever the aetiology of the CLD, signs of both necrosis
and apoptosis can be found in the same section, in asso-
ciation with the other events of the chronic scenario
(inflammation, fibrogenesis, angiogenesis, and so on)
[185,186]; moreover, apoptosis can indeed act in a pro-
inflammatory and pro-fibrogenic way, thus sustaining
progression of the CLD [192].
Some years ago, Kaplowitz [184] proposed that necrotic
cell death may occur in cells exposed to very high levels of
oxidative stress and be able to irreversibly damage mito-
chondria or to inactivate executioner caspases. This
indeed may happen, as shown by in vitro experiments, in
hepatocytes [19] or human HSC/MFs [189,191] exposed
to very high concentrations of HNE (50 μM or more).
However, it is not really easy sometimes to identify which
mode of cell death may predominate in different condi-
tions of liver disease. Recently, Mahli and coworkers [186]
have proposed that controversies about this specific fea-
ture may be solved by recognizing that apoptosis and
necrosis frequently represent alternative outcomes of the
same pathways leading to cell death. For example, even in
conditions able to induce caspase-dependent apoptosis
(activation of either intrinsic pathways or of death recep-
tor-related pathways), severe mitochondrial changes with
membrane depolarization and uncoupling of oxidative
phosphorylation may result in ATP depletion and, thus,
in the blocking of caspase activation and classic apoptosis.
Another relevant question is, is it really necessary to reach
high levels of oxidative stress to induce irreversible cell
death, for example, in hepatocytes? In theory, in the sce-
nario of a CLD, oxidative stress should be quantitatively
mild to modest on a tissue basis, but it is conceivable that
additive or synergic factors may overlap, leading to higher
levels that may locally (for example, in the site of an
inflammatory flare) or, even more likely, at the level of the
single cell 'make' or 'mark' the difference for one or more
cells to survive or die. Two concepts should be stressed
(interested readers can find more details in
[107,136,186,187,190,192-195]. First, necrosis or cas-
pase-independent cell death is no longer seen as an acci-
dental and uncontrolled form of cell death but is
beginning to be envisaged as the result of crosstalk
between several biochemical and molecular events,
including an interplay between crucial signalling path-
ways [193]. ROS and increased levels of intracellular cal-
cium are believed to be the main players in this scenario
and necrosis, in vivo and in vitro, may function as a sort of
back-up program when caspase activation is impaired.
Second, both caspase-independent cell death and apopto-
sis, particularly when related to the engagement of death
receptors (DRs) or Toll-like receptors (TLR) by their
respective ligands, critically involves the kinase RIP
(Receptor interacting protein), which is currently seen as
one of the crucial, and redox sensitive, cellular crossroads
determining whether cells live or die (Figure 22).
In the next sections a number of concepts and mecha-
nisms involved in ROS-dependent and 'aetiology-related'
forms of hepatocyte death are outlined to possible serve as
a paradigm to understand the extremely complex scenar-
ios occurring in CLDs.
ROS and mitochondria in cell death
Alterations of mitochondria have a role in different types
of either caspase-dependent or caspase-independent cell
death [196] and are strictly associated with ROS. If mito-
chondrial integrity is deranged, this will be associated
with the dissipation of the mitochondrial inner trans-
membrane potential (ΔΨm), leading to mitochondrial
outer membrane permeabilization and release of pro-
apoptotic proteins such as cytochrome c, Smac, Diablo
and AIF, leading then to apoptosis. Increased permeabili-
zation of the mitochondrial outer membrane can also
lead to increased intracellular ROS generation as a conse-
quence of damage to the mitochondrial electron transport
chain. ROS may also increase permeabilization of mito-
chondrial outer membrane by altering thiol groups of
ANT (Adenine nucleotide translocase) or VDAC (Voltage-
dependent anion channel), the latter being required for
superoxide anion efflux from mitochondria. The overall
message then is quite simple: mitochondria can represent
not only a source of ROS but also a target for their action
in relation to cell death.
Death receptor activation, ROS, NF-κB and sustained 
activation of JNK: to die or not to die, that is the question
Probably the best detailed example of ROS involvement
in cell death is related to the activation of death receptors,
the mitochondria-related generation of ROS and the sub-
sequent sustained activation of JNK. Activation of path-
ways leading to increased mitochondrial ROS generation
and related to cell death (apoptotic or not) may be elicited
by TNF, mainly by acting on the TNF receptor TNFRI, but
a significant role for ROS has also been described in the
activation of Fas as well as other death receptors, such as
DR-4 and DR-5 [107]. The reader can then easily under-
stand the intrinsic relevance of what we are going to
describe by thinking about the complex scenario of CLDs
of different aetiology, where chronic inflammation and
ligand-mediated activation of death receptors is a veryFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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common event (reviewed in [186]). TNF interaction with
its type I receptor will generate a complex sequence of
events (more detail is given in Figure 23) that are designed
to lead either to survival or cell death, with ROS forcing
them towards the latter [197-202]. Indeed, TNF-TNFRI
interaction may serve as a paradigm for describing the role
of ROS (here generated mostly by mitochondria) since
(see below) several conditions leading to the increased
generation of ROS will converge on sustained JNK activa-
tion and its consequences. Interestingly, TNF (Figure 23)
may even lead to ROS-dependent and JNK-mediated
necrotic cell death through the activation of Nox1: how-
ever, this has been described in fibroblasts and, at present,
we do not know whether it may apply to hepatocytes or
other liver cell populations [195,202].
ROS-dependent sustained activation of JNK: a common 
step in oxidative stress-dependent cell death
Mitochondria-derived ROS are implicated in TNF-
dependent apoptotic and non-apoptotic cell death by
inducing a ROS-dependent sustained activation of JNK
(Figure 24), the latter being an event commonly seen in
other conditions resulting in increased generation of ROS
[107,186,187,193,199,203,204]. Several mechanisms
Receptor interacting protein (RIP) kinase 1 as a crucial cellular crossroads affecting whether target cells survive or die Figure 22
Receptor interacting protein (RIP) kinase 1 as a crucial cellular crossroads affecting whether target cells survive or die. ROS 
may increase in the cells also as a consequence of increased release by mithocondria, as in the case of TNFα and FasL-related 
responses. Activation of death receptor (DR), Toll-like receptors (TLRs) as well as signalling pathways initiated upon detection 
of intracellular stress (including oxidative stress itself and/or DNA damage) all have been reported to converge on RIP, partic-
ularly RIP1; the cellular context will then drive the RIP-related response of target cells towards survival by preferentially induc-
ing activation of NF-κB and/or MAPK, or to cell death by inducing either true apoptosis or a form of caspase-independent cell 
death [193], although this is an oversimplified scheme (for example, sustained JNK activation is a well known event leading to 
cell death).
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Figure 23 (see legend on next page)
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have been described to explain ROS-mediated activation
of JNK but three should be considered. The group of Karin
has described for TNF-mediated cell death that ROS are
able to inhibit JNK phosphatases, which are the JNK-inac-
tivating enzymes [203,204]. Alternatively, it has been
described that ROS may act by removing a thioredoxin-
dependent inhibitory action on the JNK upstream kinase
ASK1 (MAP3K) [104,205,206], although others [203]
were not able to confirm ASK1 involvement in TNF-medi-
ated cell death. ROS may even operate by inducing a
PARP-1 over-activation resulting in depletion of NAD+
and ATP as well as in a downstream involvement of
TRAF2/RIP1 mediating sustained JNK activation and cell
death, but it is still unclear how TRAF2 and RIP1 may be
involved following PARP-1 activation [207,208].
Whatever the mechanism, there is no doubt that ROS-
dependent sustained JNK activation can promote cell
death, being effective in inducing mitochondrial outer
membrane permeabilization; although there is still some
controversy on the molecular 'targets' of ROS-activated
JNK, a number of hypotheses [187,194,199,209] have
been proposed to explain this JNK-mediated event (sum-
marized in Figure 24). The reader should also remember
that NF-κB will act to prevent cell death by a number of
mechanisms, some of them potentially affecting ROS-
mediated sustained JNK activation, such as specifically the
reported up-regulation of SOD-2 (that is, the mitochon-
drial SOD isoform), in TNF-dependent cell death [210].
According to the protective role of NF-κB, it has been
shown that NF-κB inhibition can indeed sensitize hepato-
TNF-induced and ROS-dependent events in target cells: the role of JNK activation in mediating cell death Figure 23 (see previous page)
TNF-induced and ROS-dependent events in target cells: the role of JNK activation in mediating cell death. TNF interaction with 
its type I receptor will generate a sequence of events (depicted in Figure 23) that is not designed to lead uniquely to cell death 
[197-200] and in which ROS may play a crucial role. 1) The interaction between TNF and TNFRI is first followed by association 
with the intracytoplasmic receptor tail of the adapter TRADD (TNF-receptor associated death domain), the protein kinase 
RIP1 and TRAF-2 and TRAF-5 (TNF-receptor associated factors 2 and 5); this works as a signalling complex that activates NF-
κB (through Inhibitor of NF-κB kinase (IKK)) and MAPK cascades that regulate the AP-1 transcription factor. Activation of NF-
κB-binding activity and transcription of dependent genes is potentially pro-survival by up-regulating the synthesis of cFLIP (c 
FLICE inhibitory protein), which can inhibit activation of caspase 8/10, the starting point for TNF-mediated induction of classic 
apoptosis. 2) At this point the TRADD/RIP-1/TRAF-2 complex can dissociates from the receptor by a still unknown mecha-
nism and bind to FADD (Fas-ligand associated death domain) to form another complex leading to recruitment of several mole-
cules of pro-caspase 8/10 and to their autocatalytic cleavage, resulting in activation; however, this event occurs only in cells 
having low levels of cFLIP, suggesting that apoptosis as well as caspase-independent or necrotic cell death (see later) may occur 
when the preventive pro-survival function of NF-κB fails. When activation of caspase 8/10 ocurs, the scenario can still prefigure 
two alternatives. 3) Activated caspase 8/10 may cleave the pro-apoptotic protein Bid (to tBid), which then translocates to 
mitochondria, causing permeabilization of mitochondrial outer membrane, cytochrome c release, apoptosome assembly and 
activation of executioner caspases, leading to classic apoptosis. This pro-apoptotic scenario may be amplified by the recruit-
ment to TNFRI of FAN (Factor-associated neutral sphingomyelinase), which is able to produce sphingosine that, in turn, per-
meabilizes lysosomal membranes, leading to the release of cathepsins. These lysosomal proteases, which can be activated 
following engagement of different death receptors, act as pro-apoptotic proteases able to cleave Bid as well as to induce oli-
gomerization of Bax or interact directly with mitochondrial outer membrane (note that this pathway, for the sake of clarity, 
has been omitted from Figure 23). It should be noted that in hepatocytes it has been reported that generation of ROS following 
activation of death receptors (by Fas or TNF) is strictly dependent on Bid cleavage to tBid and its subsequent translocation to 
mitochondria [201]. 4) The second alternative is the one more strictly related to ROS and involves the crossroads kinase RIP1. 
RIP1 has multiple crucial roles; it is involved in the activation of NF-κB, but may also contribute to apoptosis when cleaved by 
caspase-8 to cRIP1 (4a), an event preventing or reducing activation of NF-κB and sustaining enhanced interaction between 
TRADD, FADD and procaspases 8/10. However, it has also been described (4b) that the kinase domain of RIP1 is essential to 
activate JNK, which in turn (although this is just one of the JNK-dependent actions) will favour TNFRI-related apoptosis and 
mitochondrial outer membrane permeabilization by eliciting cFLIP phosphorylation and degradation. Concerning the involve-
ment of ROS, however, RIP1 (reviewed in [107,193,194]) has been shown (5) to be able also to translocate to mitochondria 
(prevented by NF-κB) following TNF stimulation of cells: this event induces mitochondrial outer membrane permeabilization 
and increases release of ROS in the cytoplasm without leading to cytochrome c release and apoptosome complex formation. 
This increased TNF-related mitochondrial generation of ROS is crucial because it can lead target cells to apoptosis or, more 
likely, to a necrotic or caspase-independent form of cell death: in this latter scenario a significant role is attributed to ROS-
mediated sustained activation of JNK (6), surely operating in hepatocytes [186,187], which, as we will see (Figure 24), is a cru-
cial crossroads for ROS-related irreversible injury of parenchymal cells as elicited by the different aetiologies leading to CLDs. 
TNF (7) may lead to ROS-dependent and JNK-mediated cell death (necrotic type) also by involving activation of Nox1: how-
ever, this mechanism has been described in fibroblasts and, at present, we do not know whether it may apply to hepatocytes or 
other liver cell populations [195,202].Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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ROS-dependent sustained activation of JNK isoforms as a crucial event in inducing cell death Figure 24
ROS-dependent sustained activation of JNK isoforms as a crucial event in inducing cell death. ROS-mediated sustained activa-
tion of JNK isoforms is likely to rely on inhibition of JNK phosphatases and/or activation of the upstream kinase ASK-1, finally 
resulting in mitochondrial outer membrane permeabilization. To explain this later, crucial event, the following hypotheses have 
been proposed: a) JNK may, in a caspase-independent way that has still not been characterized, promote the cleavage of the 
BH3 domain of Bid, resulting in the production of jBid, which should operate in a pro-apoptotic way similarly to tBid [209]; b) 
JNK may favour apoptosis by increasing proteasomal degradation of cFLIP (the inhibitor of pro-caspase 8/10 activation) by acti-
vating the ubiquitin ligase Itch [199]; c) by pro-apoptotic modifications of proteins belonging to the Bcl-2 family, such as Bax or 
Bcl-XL [187,194].
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cytes to TNF-induced apoptosis by means of JNK sus-
tained activation [211].
Free fatty acids, endoplasmic reticulum stress, oxidative 
stress and cell death: hepatocyte injury in NAFLD and 
other CLDs
As elegantly reviewed by Parekh and Anania [143], liver
injury in NAFLD can be considered essentially as the con-
sequence of increased hepatocyte stores of FFAs. Overall,
the most relevant mechanisms leading to hepatocyte
injury in these metabolically altered conditions involve an
excess of FFAs: directly inducing hepatocyte apoptosis and
stimulating production of TNF, which is considered in
this context as an adipocytokine; increasing Fas ligand
binding to Fas (CD-95) receptor in steatotic hepatocytes,
leading to apoptosis; leading to impaired mitochondrial
or peroxisomal β-oxidation of FFAs accumulating in hepa-
tocytes ” as previously described (see the section 'ROS and
oxidative stress-related reactive intermediates in NAFLD
and NASH: their generation and the role in causing stea-
tosis'), this eventually leads to generation of ROS and
lipid peroxidation products, mainly HNE, which in turn
may cause cell injury and death; inducing ER stress and
the so-called 'unfolded protein response' (UPR), which is
potentially able to result in the induction of a form of cas-
pase-dependent cell death involving mitochondria.
The first three mechanisms are all intrinsically related to
ROS generation, as already described. If the interplay
between FFAs, ER stress and oxidative stress is considered,
the scenario can be summarized as follows (more details
in [212,213]). In normal conditions the ER is the site
devoted to protein entry into the secretory pathway. The
ER environment involves a protein-folding machinery
that is based on protein chaperones, proteins designed to
catalyze folding and proteins and systems able to sense
and detect unfolded or misfolded proteins. The latter sys-
tems prevent secretion of misfolded proteins and direct
them to be degraded; UPR signalling pathways, specifi-
cally designed to avoid accumulation of unfolded pro-
teins in the ER lumen, are essential for adaptation to
altered homeostatic conditions, including redox changes.
In this context, two concepts should be underlined: first,
the ER is a unique oxygen folding environment in which
disulfide bonds can be formed ” unfortunately, even in
normal conditions protein folding can lead to ROS gener-
ation, likely as by-products of protein oxidation occurring
in the ER; and second, oxidative stress, whatever the
source, can affect ER and activate UPR, the latter initially
operating as an adaptative mechanism to preserve cell
function and favour cell survival. Several environmental
or metabolic insults may then result in an alteration of
protein folding within the ER [212,213], including redox
changes, depletion of calcium, energy deprivation, ele-
vated protein traffic within the ER compartment, altered
post-translational modifications and impairment of glyc-
osylation and Golgi processing and, as also described in
the case of NAFLD, excess storage of FFAs (reviewed in
[143]). Indeed, signs of ER stress have been detected in
hepatocytes of mice fed high fat diets or ob/ob mice (mice
deficient in leptin that are obese and diabetics), including
phosphorylation of pancreatic ER kinase (PERK), transla-
tion initiation factor 2 (TRAF2) and JNK. Moreover, ER
stress has been shown to exacerbate hepatocyte insulin
resistance [214]. Figure 25 summarizes the most relevant
features of ER stress, following accumulation of FFAs and
also involving oxidative stress and ROS, the latter once
again significantly contributing to multiple pathways
leading to hepatocyte death (for more details, see
[212,213]).
ER stress-induced apoptosis has also been implicated in
chronic hepatitis C and ALD [186]. With respect to HCV,
several studies have shown that HCV-related proteins,
including either core proteins as well as E1 and E2 pro-
teins of the envelope, are able to induce overexpression of
C/EBP homologous protein (CHOP) via the UPR
response, ER depletion of calcium, and apoptosis in liver
cells (HCV replicon cells) [215,216]. Moreover, ER stress
and apoptosis were also found in the livers of HCV core
transgenic mice [215]. More recently, it has been reported
that activation of the Gadd153 gene by HCV in HCV rep-
licon cells is able to sensitizes these cells to oxidant injury
[217] and that both HCV and, interestingly, HBV proteins
are able to induce ER stress and to up-regulate protein
phosphatase 2A (PP2A) through activation of CREB
[218]. In the case of ALD, ER stress involvement has been
attributed to hyper-homocysteinemia, since betaine treat-
ment in a mouse model of ALD can promote removal of
homocysteine and prevent not only ER stress but also liver
steatosis as well as induction of apoptosis. Excellent
reviews dedicated to ER stress and HCV- or alcohol-related
liver injury published recently by Kaplowitz and cowork-
ers [219-221] also take into consideration the role of ROS.
Ethanol-related redox mechanisms leading to 
mitochondrial damage and hepatocyte apoptosis
This section and Figure 26 offer a number of additional
concepts (see also the section 'Chronic ethanol consump-
tion and metabolism: induction of oxidative stress and
related events' above) that are mostly focussed on the role
of ethanol and ROS-dependent injury of mitochondria in
determining hepatocyte cell death [133-136,222].
Chronic ethanol consumption can promote intramito-
chondrial formation of ROS and decrease/deplete the
mitochondrial content of GSH, thus making mitochon-
dria even more susceptible to oxidative injury [223,224].
Lipid peroxidation has a major role in the impairment of
mitochondrial oxidative phosphorylation [223]. Mito-
chondrial DNA is oxidatively altered in animals treatedFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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with ethanol [225] and this may account for the high lev-
els of mitochondrial DNA deletions found in the liver of
alcoholic patients [226] and the ethanol-related impair-
ment of hepatic respiratory activity (presumably by affect-
ing the synthesis of subunits of the electron transport
chain encoded by mitochondrial DNA). Intramitochon-
drial generation of ROS and oxidative stress can induce
the collapse of mitochondrial membrane potential and
promote mitochondria permeability transition (MPT),
possibly by favouring Bax translocation to mitochondria
ER stress and ROS in NAFLD/NASH Figure 25
ER stress and ROS in NAFLD/NASH. This figure describes the most relevant features of ER stress following excess accumula-
tion of FFAs in hepatocytes and also involving oxidative stress and ROS (the latter may originate in NAFLD from deranged 
mitochondria, CYP2E1 and CYP4A isoforms, or from peroxisomes). On the basis of what is described in the text (sections 
'ROS and oxidative stress-related reactive intermediates in NAFLD and NASH: their generation and the role in causing steato-
sis' and 'Free fatty acids, endoplasmic reticulum stress, oxidative stress and cell death: hepatocyte injury in NAFLD but not 
only'), the following major features can be offered. a) When the UPR response fails to solve the problem of protein folding 
caused by different conditions able to induce ER stress (see text for details), including increases in FFA levels, this is followed 
by an induction of apoptotic cell death that can use both mitochondrial pathways as well as other independent pathways. b) 
ROS and oxidative stress are able to disrupt ER functions, a major cause seemingly being ROS-dependent increased release of 
calcium from ER stores: excess calcium has been reported to induce mitochondrial outer membrane permeabilization and, in 
turn, increased mitochondrial ROS release as a further contribution to increased intracellular levels by other sources and 
causes operating in NAFLD-related hepatocytes. c) In such a complex scenario, ER stress can result in apoptosis by a number 
of mechanisms, including: damage to mitochondria leading to cytochrome release, apoptosome formation and related sequen-
tial activation of executioner caspase 9 and 3; IRE-1 recruitment of TRAF-2 in order to activate either ASK-1 and then JNK, a 
potentially pro-apoptotic pathway that can be further sustained by ROS, or (at least in mice) caspase 12, which, in turn, can 
activate caspases 9 and 3; and activation of PERK and ATF6 (p90), which can lead through nuclear translocation of ATF4 and 
ATF6(p50), respectively, to transcriptional up-regulation of CHOP, a factor that promotes apoptosis by either inhibiting 
expression of Bcl-XL or up-regulating expression of pro-apoptotic proteins such as Gadd34, Trb3 and Dr5.
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[225,227]; induction of MPT can, alternatively, lead to
mitochondrial swelling and then to necrotic cell death as
well as to cytochrome c release and induction of caspase-
dependent apoptosis [196,228-230]. The hepatic inflam-
matory reaction may have a role in ethanol hepatotoxic-
ity, with a major role attributed to activated Kupffer cells
(reviewed in [133,135,231]), in which ethanol may
'switch on' a ROS- and NF-κB-related cycle leading to an
amplified release of TNF; indeed, hepatocytes undergoing
ethanol-induced oxidative stress may be more sensitive to
the pro-apoptotic action of TNF [232], including
increased sensitivity to TNF-related MTP, which may also
depend on ROS- or HNE-mediated changes to ERK1/2- or
PI3K-related survival signals [233,234].
Mitochondria, nitric oxide, RNS and cell death
NO and related RNS are additional key players in the
chronic inflammatory settings that characterize chronic
wound healing and, more specifically, fibrogenic CLDs.
NO and RNS theoretically can promote or prevent apop-
totic cell death by interfering with either mitochondria-
dependent or mitochondria-independent signalling path-
ways [235-238]. The most relevant feature is represented
by the cellular redox state, with major determinants being
the steady state concentration of ROS (mainly O2
￿-) and
the rate between ROS and NO generation; as a rule, NO
can act in a preventive way when ROS levels are low and
vice versa [235-238].
Cytoprotective action is likely to rely on NO-dependent
inhibition of ￿OH generation in the presence of an iron-
catalysed Fenton reaction or on inhibition of propagation
of lipid peroxidation (NO being able to react with lipid
alkoxyl or lipid hydroperoxyl radicals). In the presence of
higher levels of ROS, the right NO/O2
￿- ratio or the right
levels of O2, NO may lead to the generation of highly reac-
tive RNS, such as N2O3 or ONOO-, at levels that are able
to induce more aggressive oxidation, nitrosation/S-nitro-
The central role of mitochondrial damage in ethanol-dependent and ROS-mediated hepatocyte injury Figure 26
The central role of mitochondrial damage in ethanol-dependent and ROS-mediated hepatocyte injury.
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sation and nitration of different biological macromole-
cules, eventually leading to either necrotic or apoptotic
cell death. Figure 5 summarizes these two alternative sce-
narios (that is, preventive versus injurious) that can be
elicited by NO and RNS, with emphasis on the major
molecular mechanisms that may be involved (more
details in [235-243]). Here one should just recall that if
liver injury is concerned, NO levels (and then those of
RNS) are usually increased in CLDs as a consequence of
up-regulation of iNOS in hepatocytes, endothelial cells,
Kupffer cells and, possibly, HSC/MFs [235-238,241,242].
This is likely to be significantly related to levels of TNF in
the chronic inflammatory environment as well as to
increased translocation of gut-derived endotoxins to the
portal circulation, as clearly described in the case of
chronic ethanol ingestion and the subsequent interaction
of endotoxins with CD14 and TLR-4 in Kupffer cells
[243].
Oxidative stress and induction of cell death in HSC/MFs
In the past decade an emerging issue in hepatology has
been that liver fibrosis and even cirrhosis may be poten-
tially reversible. Recovery from either acute or chronic
liver injury in animal models is characterized by apoptosis
of HSC/MFs, reduction of TIMP (tissue inhibitor of metal-
loproteinases) levels and progressive degradation of fibril-
lar fibrotic ECM. In this scenario, the sensitivity of HSCs
and HSC/MFs to pro-apoptotic stimuli has been investi-
gated to gain basic knowledge for a putative cell targeted
antifibrotic therapy [79-82,91,94,95,244]. Pertinent to
this review, HSC/MFs exposed to oxidative stress can
undergo caspase-independent cell death but this usually
requires very high concentrations of either H2O2, O2
￿- or
HNE, which are hardly comparable with levels observed
in vivo [94,189,246]. This has been substantiated mainly
for human cells, which, perhaps, may be more resistant
than activated rat or murine cells, possibily because
human HSC/MFs when activated overexpress Bcl-2 and
other survival pathway proteins [94].
The overall message is that HSC/MFs are likely to survive
the conditions of oxidative stress usually operating in
CLDs, and rather (see below) are more likely to sustain
their pro-inflammatory and pro-fibrogenic responses.
Redox mechanisms and chronic inflammatory 
response in CLDs
Perpetuation of inflammatory response is a major aetiol-
ogy-independent driving force for fibrogenic progression
in CLDs. In such a chronic scenario, ROS and other reac-
tive intermediates or pro-oxidants (for example, HOCl)
released by activated inflammatory cells, either resident
(that is, Kupffer cells) or recruited from peripheral blood,
may significantly contribute to injury perpetuation. How-
ever, they may also (particularly ROS and HNE) act in a
paracrine way to affect the response of surrounding cells.
Mediators of oxidative stress, whatever the source (includ-
ing also ER stress [247]), the aetiology or metabolic con-
dition can trigger or modulate expression of pro-
inflammatory cytokines and chemokines in inflammatory
cells and HSC/MFs, mostly through activation of NF-κB
[15,107]. However, oxidative stress mediators also have a
significant role in mediating the pro-apoptotic/necrotic
effects of certain cytokines, with TNF being possibly the
paradigm [107,186,187,248,249]. This scenario is of par-
ticular relevance in some CLDs, such as in human ALD or
experimental BDL [243,250]: both ethanol ingestion or
experimental cholestasis can lead to significant transloca-
tion of gut derived endotoxins to the portal circulation,
where they interact with the surface receptor CD14, result-
ing in activation of Kupffer cells and increased synthesis of
pro-inflammatory cytokines (mainly TNF), eicosanoids,
and, once again, ROS and NO. With TNF being an impor-
tant cause of hepatotoxicity in CLDs, one should recall
that hepatocytes are resistant to the pro-apoptotic action
of TNF because of the concomitant pro-survival involve-
ment of the NF-κB and PI3K pathway: it is once again the
increase in intracellular oxidative stress that can alter the
balance, rendering hepatocytes more susceptible to TNF-
induced cell death.
Functional responses of inflammatory cells to oxidative 
stress-related intermediates
Apart from the NF-κB-related increased expression of
inflammatory cytokines and chemokines [15,106,107],
ROS and RNS may act as signalling intermediates by acti-
vating tyrosine kinases and inhibiting tyrosine phos-
phatases, resulting in an enhancement of tyrosine
phosphorylation events known to regulate anti-microbial
and host defence functions in leukocytes [251-253]. The
following concepts should be underlined. First, ROS are
likely to be involved in the process of phagocytosis, possi-
bly by leading to amplification of the stimulating signal
that follows engagement of Fc receptors on the surface of
phagocytic cells, as reported for neutrophils, where ROS
seem able to increase either the cross-linking of the FcãRI-
IIb [254], as well as by contributing, in neutrophils and
macrophages, to amplification of the signal by modulat-
ing the activity of the tyrosine kinase Syk, a FcãR down-
stream signalling element [255]. Second, ROS-mediated
inhibitory modulation of the activity of PTPs (for exam-
ple, CD45, SHP-1, HePTP) has been shown to regulate
signalling events involved in the activation of T lym-
phocytes [256,257]. In addition, CD45 has long been
shown to be relevant for LTB4- and C5a-induced chemo-
taxis and low affinity FcãR signalling in neutrophils
[258,259]: since ROS have been shown to be potent
inhibitors of CD45 [260], they may interfere with physio-Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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logical responses to these chemoattractants. Third, ROS
may have a role in the apoptosis-related removal of leuko-
cytes during inflammatory responses, as clearly shown for
neutrophils and other cells, again by involving tyrosine
phosphorylation, CD45 and SHP-1 [261-264], but also
through the NOX-dependent, Lyn-mediated activation of
the inositol phosphatase SHIP [265]. Similarly, peroxyni-
trite has also been shown to enhance apoptosis in leuko-
cytes [266,267].
An additional concept is that intermediates able to cross
the leukocyte plasma membrane may affect, in a paracrine
way, the behaviour of surrounding cells, as shown origi-
nally for endothelial cells [268,269] and now accepted for
many other cells with roles in chronic pro-inflammatory,
angiogenic and fibrogenic environments. Accordingly, the
lipid soluble aldehyde HNE, at levels compatible with
those described in CLDs, up-regulates the expression of
the pro-fibrogenic cytokine TGFβ1 in both rat Kupffer
cells and human monocyte/macrophage cells [270].
These data may help to explain the scenario observed
when using the in vivo experimental CCl4-dependent
chronic model: administration of α-tocopherol to rats
undergoing this protocol resulted not only in a reduction
of oxidative stress, lipid peroxidation and HNE, but also
in decreased synthesis of both collagen type I and TGF β1
[271,272]. Moreover, HNE and other HAKs have been
reported to stimulate leukocyte chemotaxis at very low
concentrations (0.1 μM; reviewed in [21,35,55]), suggest-
ing that α-tocopherol and other chain-breaking antioxi-
dants may prevent experimental liver fibrosis (reviewed in
[21,35,36,55]) by either preventing or inhibiting selected
phenotypic responses of activated MF-like cells (see the
section 'Redox mechanisms in liver fibrogenesis: pro-
fibrogenic cells as a functional target' below) or, at least in
part, by inhibiting leukocyte recruitment due to HNE or
HAKs. Indeed, both ROS and HNE have been shown to
up-regulate MCP-1 expression in vivo and in vitro, and
then to sustain recruitment/activation of monocytes/mac-
rophages and Kupffer cells as well as to attract HSC/MFs
[76,273,274].
Pro-inflammatory response of activated HSC/MFs to ROS 
and HNE: the strange case of MCP-1
A peculiar example of interplay between the generation of
reactive intermediates from oxidative stress, inflammatory
response and fibrogenesis is represented by the case of
MCP-1 (CCL2), which can recruit and activate monocytes
and T lymphocytes and plays a major role in the forma-
tion and maintenance of the inflammatory infiltrate in
different pathological conditions [275-281]. MCP-1,
which is overexpressd in human CLDs and experimental
models of liver injury [273,282,283], can be synthesised
by activated macrophages and Kupffer cells as well as by
HSC/MFs and biliary epithelial cells [283,284]. With
regard to HSC/MFs, MCP-1 expression is stimulated by
pro-inflammatory cytokines, such as IL-1 and TNF
[282,283], thrombin [285], engagement of integrin recep-
tors [285] and both ROS and HNE [273,286]. Indeed, as
for TNF or other chemokines such as IL-8 and RANTES,
MCP-1 depends on the activation of the redox sensitive
transcription factors AP-1 and NF-κB [287]. In human
HSC/MFs, ROS can stimulate MCP-1 expression through
involvement of NF-κB, whereas HNE does not involve
NF-κB and more likely operates through an AP-1-related
mechanism [288], possibly involving activation of PKC
[282], as shown for the PKCβ isoform in monocyte/mac-
rophage cell lines [289].
Finally, data on human and rat fibrotic livers indicate a
direct correlation between oxidative stress, hepatic levels
of MCP-1 and the number of monocytes infiltrating the
injured liver [273,284]. Moreover, MCP-1 can signifi-
cantly stimulate chemotaxis of human HSC/MFs, another
putative redox-sensitive pro-fibrogenic feature [290].
Redox mechanisms in liver fibrogenesis: pro-
fibrogenic cells as a functional target
In this section relevant data will be recalled (most refer-
ring to HSC/MFs) and considered within a 'myofibrob-
last-centric' view (Figure 27), in which pro-fibrogenic
responses of MF-like cells can be affected by both extra-
and intracellularly generated ROS and HNE.
Pro-fibrogenic action of oxidative stress revealed by 
antifibrotic action of antioxidant molecules
The hypothesis of a causative involvement of oxidative
stress in fibrogenesis relies on an impressive number of
experimental studies leading to the same final scenario:
antioxidant supplementation is able to significantly pre-
vent fibrotic progression in animal models of CLDs by
reducing the extent of oxidative stress and/or lipid perox-
idation (reviewed in [35,36], with comments in the sec-
tion 'Antioxidants as antifibrotic therapeutics for CLDs?'
below). The first antioxidants used were silymarin
[291,292], α-tocopherol [271,272], silybin [174] and S-
adenosylmethionine [293], and most laboratories were
able to describe a temporal sequence of events, suggesting
overall that oxidative stress and lipid peroxidation pre-
cede or are concomitant with HSC activation and collagen
deposition [294-297]. Similarly, experimental studies
have also reported that NO was able to prevent both lipid
peroxidation and collagen deposition [298,299].Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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HNE and ROS can up-regulate pro-collagen type I 
expression in HSC/MFs: a puzzle that in the end makes 
sense
ROS and HNE exert a direct pro-fibrogenic action on HSC/MFs: the 
paracrine effect disclosed
Up-regulation of pro-collagen type I by both ROS and
HNE in activated HSC/MFs is a relevant finding that has
been confirmed by several different laboratories using
either cells of human or rat origin. The first published
study in 1993 [300] was on human HSC/MFs exposed to
very low levels of HNE (1 μM), resulting in the strongly
increased expression of pro-collagen type I, which was
prevented by pre-treatment of cells with either vitamin E
or the synthetic antioxidant diphenyl-phenylendiamine.
After that study, the susceptibility of rat or human HSC/
MFs in terms of pro-collagen type I synthesis to oxidative
stress mediators was analysed and confirmed using differ-
ent experimental strategies. The first strategy adopted in
the 1990s was to expose HSC/MFs to extracellularly avail-
able mediators [189,301-305], including H2O2, O2
￿- gen-
erated by the xanthine/xanthine-oxidase system, MDA,
HAKs of different chain length, and the conditioned
medium of normal hepatocytes undergoing oxidative
stress [304,305]. Up-regulation of pro-collagen type I was
also obtained later by co-culturing HSC/MFs (which do
not express CYP2E1 [137]) with hepatocytes transfected
to overexpress CYP2E1 and then exposed to conditions
(for example, ethanol) that result in paracrine exposure of
HSC/MFs to CYP2E1-dependent ROS generation
[306,307]. More recently, the connection between oxida-
tive stress, lipid peroxidation and collagen synthesis has
once again been confirmed by exposing rat HSC/MFs to
F2-isoprostanes [308]. With regard to the pro-fibrogenic
mechanism, HNE has been shown in human HSC/MFs to
elicit transient activation of JNK isoforms and their
nuclear translocation as well as to lead to up-regulation of
c-Jun and increased AP-1 binding to DNA [288]; a very
similar JNK/AP-1-dependent pattern, inducing up-regula-
tion of collagen type I, has been shown to operate in rat
HSC/MFs exposed to UV irradiation [309]. The overall
take-home message from these early studies was clear:
ROS, mainly H2O2, HNE and HAKs of different chain
length, released in a paracrine way by damaged hepato-
cytes, endothelial cells or activated inflammatory cells,
can easily cross the membrane of HSC/MFs and lead to
increased synthesis of pro-collagen type I, a significant
ROS and related mediators as pro-fibrogenic stimuli: a 'stellate centric' view Figure 27
ROS and related mediators as pro-fibrogenic stimuli: a 'stellate centric' view.
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component of the fibrillar-like ECM in fibrotic and cir-
rhotic livers.
ROS generated within HSC/MFs up-regulate collagen type I: the 
focus is now within the target pro-fibrogenic cell
The next step forward was provided by a series of elegant
studies by Nieto and coworkers [306,310,311], who
adopted the strategy of transfecting rat HSC/MFs to
express human CYP2E1: pro-collagen type I transcription
and synthesis in transfected cells was proportional to the
levels of CYP2E1 and exacerbated by exposure of cells to
ethanol or arachidonic acid (that is, conditions leading to
CYP2E1-related increased generation of ROS) and pre-
vented by using either antioxidants or specific inhibitors
of CYP2E1, such as diallylsulfide. Around the same time,
another part of the puzzle was revealed by showing that
TGFβ1, the most potent pro-fibrogenic cytokine, was able
to up-regulate collagen type I in HSC/MFs by eliciting
H2O2-dependent signalling involving the binding of p35
C/EBPβ protein to a specific region of the promoter of the
collagen α1(I) gene [305], an action possibly related to
modulation of intracellular levels of GSH [312] and/or
the involvement of p38MAPK [313]. Other signalling
pathways and elements have been proposed to mediate
ROS-dependent collagen type I expression, including up-
regulation of cyclooxygenase 2 [311] or the redox sensi-
tive transcription factor Sp-1 [304,314], but it should be
noted that again the H2O2-dependent involvement of the
same C/EBPβ protein was found also to mediate acetalde-
hyde (ACA)-stimulated up-regulation of collagen type I
gene expression [315]. The ACA effect on HSC/MFs was
biphasic, with an early phase being mediated by ACA and
a late effect due to ACA-induced up-regulation of TGFβ1
expression [316]. The authors suggested in the end that
ACA and TGFβ1 were eliciting similar, but not identical,
mechanisms to up-regulate collagen type I expression.
ACA has also been shown to up-regulate collagen type I
expression through activation of JNK, similar to what was
also found for HNE [288] and UV exposure [309], as
finally mediated by the DNA binding protein BTEB [317].
More recently, intracellular generation of H2O2 has been
shown to mediate leptin-stimulated enhancement of α
1(I) collagen gene expression in immortalized LX-2
human HSCs [318]: H2O2 was shown to activate Erk1/2
and p38MAPK through active involvement of Janus
kinases 1 and 2 (JAK1 and JAK2).
If one considers that extracellular ROS, HNE and F2-iso-
prostanes are all able to up-regulate TGFβ1 synthesis in
either HSC/MFs or mononuclear cells [270,308,317],
another concept emerges: both the expression and activity
of the pro-fibrogenic cytokine TGFβ1 are modulated by
ROS or other mediators produced within the target cell, by
surrounding cells (in a paracrine manner) or, as suggested
for the case of ACA [316], even in an autocrine manner.
Intracellular generation of ROS can occur in association with 
cytokine-receptor interaction: NOX isoforms come into the liver 
fibrogenesis playground
In 2003, Bataller and coworkers [318] were the first to
identify the presence of components of NOX in HSC/MFs,
suggesting that the pro-fibrogenic action of Ang II, as
already delineated in in vivo and in vitro studies [319,320],
is dependent on the associated activation of NOX and the
related ROS-dependent activation of MAPKs, phosphor-
ylation of c-Akt and increased AP-1 DNA binding activity
[318], events blocked by the specific NOX inhibitor DPI
(diphenyl-phenyleneiodonium) or the inhibitor of Ang II
type 1 receptor (AT1), losartan. More details on the pro-
fibrogenic action of Ang II in reference to the related role
of NOX can be found in specific reviews [47,48]. The acti-
vation of NOX and intracellular generation of ROS have
been involved in the up-regulation of collagen type I
expression in HSC/MFs after engulfment by apoptotic
bodies from dead hepatocytes [97], a finding similar to an
earlier report showing that macrophage engulfment of
apoptotic bodies resulted in increased transcription of
TGFβ1 [321]. The initial report by Canbay et al. [97] was
followed by further studies unequivocally showing that
apoptotic bodies included in HSC/MFs were signalling
through NOX and ROS to up-regulate collagen α 1(I)
expression [322].
ROS and HNE affect other phenotypic responses of HSC/
MFs: the specific mediator can make the difference
ROS, but not HNE, mediate proliferation of HSC/MFs
Activation of HSCs as well as proliferation of HSC/MFs
have been suggested to rely on the activation of NF-κB as
well as on the expression of the c-myb proto-oncogene
(reviewed in [323]). Indeed, when rat HSC/MFs are co-
cultured with HepG2 cells overexpressing CYP2E1 as a
source of ROS, they start to express α smooth muscle actin
(α-SMA; a marker of MF-differentiation) and to prolifer-
ate [324]. These effects have been prevented by using anti-
oxidants or inhibitors of the Na+/K+ exchanger [323,325-
328]. It has been suggested that the mitogenic action of
ROS may rely on a crucial cysteine residue in Raf-1, MEK
and Erk signalling elements; indeed, treatment of HSC/
MFs with N-acetylcysteine is followed by activation of Erk,
phosphorylation of the transcription factor Sp1 and up-
regulation of p21Cip1/WAF1 expression, eventually lead-
ing to cell cycle arrest in G1 phase [329]. More recently,
Adachi  et al. [330] have proposed that the mitogenic
action of PDGF-BB (see also Figure 28), and possibly also
its chemotactic activity, may rely on ROS generation
through involvement of NOX, leading to activation of
MAPKs, particularly p38MAPK. In these experiments, per-
formed on a human immortalised line of HSCs and on
murine HSC/MFs, DPI was able to prevent the PDGF-BB-
dependent proliferative response, which was restored by
adding H2O2 together with PDGF-BB. Ang II has also beenFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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shown to up-regulate proliferation of HSC/MFs through
involvement of NOX and ROS [318].
Results obtained with HNE as well as with other HAKs of
different chain length substantially differ from those
obtained with ROS: HNE and HAKs do not elicit prolifer-
ation of human HSC/MFs when employed at pro-fibro-
genic doses (1”5 μM) [245,288,300,331] but rather, when
used at a pro-fibrogenic dose (1 μM), they induce a block
in DNA synthesis by selectively inhibiting PDGF-β recep-
tor intrinsic tyrosine kinase activity and downstream sig-
nalling pathways [288,331]. This peculiar effect of HNE
and HAKs is transient, with sensitivity to PDGF-BB being
recovered within 48 hours and associated with increased
expression of PDGF-β receptor subunits. Interestingly, a
similar block in PDGF-dependent signalling and prolifer-
ation has been described in human cells when exposed to
very high levels of ROS, either H2O2 or superoxide anion
[246,331].
Such a discrepancy between the effects reported for ROS
and HNE is likely to depend on the different mechanisms
of action: although Uchida and coworkers [23,332] have
proposed that, in some cells, HNE may result in mito-
chondrial damage and subsequent release of ROS (at high
concentrations, however, such as 20 μM or more) or by
trapping thiols, HNE is more likely to act as a non-oxidant
agent by forming adducts to proteins by means of nucle-
ophilic Michael type reactions [9,19,21], as shown in the
case of JNK activation [288]. Moreover, HNE does not
activate NF-κB [21,23] in human HSC/MFs [288] as ROS
do, and can even inhibit c-myb  [21], which has been
involved in ROS-mediated activation of proliferation
[323]. HNE exerts its pro-fibrogenic action only on fully
activated human HSC/MFs [21,189] and, even more rele-
vant, does not apparently act as an activating factor for rat
HSCs early in primary culture [333]. This differs from
what was suggested for ROS [75,77,80,81] and is likely to
occur because quiescent HSCs can remove H2O2 less effi-
ciently than fully activated cells [310,312], whereas HSC/
MFs are more sensitive to HNE because they lack isoforms
of GSH-S-transferase and aldehyde dehydrogenase able to
remove or inactivate HNE [288,334]. Finally, HNE seems
much more selective in its activity towards HSC/MFs,
since it causes the up-regulation of only a limited number
of genes, including those encoding collagen type I, TGFβ1,
and TIMP-1 [21,189].
ROS, but not HNE, can significantly affect chemotaxis and ECM 
remodelling in HSC/MFs: ROS as a signal to migrate
Reports from different laboratories have shown that extra-
cellular generation of O2
￿- stimulates the migration and
even invasiveness (that is, migration in matrigel) of
human HSC/MFs [246,335]. Both laboratories described
an O2
￿--dependent stimulatory effect on the Ras/Erk path-
way but opposite results for the activation of PI3K; these
effects were prevented by SOD [246,335] but were not
reproduced by exposing cells to H2O2 [246]. Migration,
particularly in matrigel, was reported to be also depend-
ent on superoxide-stimulated up-regulation of MMP-2
[335]. The idea that ROS may contribute to HSC/MF
migration has been reinforced by studies in which Ang II
[318] and PDGF-BB [330] stimulated migration in a
NOX-dependent way. Recently, a ROS contribution to
PDGF-dependent chemotaxis as well as the migratory
response to O2
￿- has been reported to critically involve
JNK activation [336] (E Novo et al., submitted). Once
again, HNE behaves in a different way since it affects nei-
ther the migration of human HSC/MFs nor the expression
of MMPs (MMP-1 and MMP-2) [189], and, differently
from O2
￿-, which has been reported to up-regulate TIMP-
2 [335], it stimulates only TIMP-1 expression [189].
A final message from this section
The final response of a pro-fibrogenic target cell to oxida-
tive stress is relatively unpredictable and significantly
affected by a number of parameters, including: the steady
state concentration of reactive species; the intrinsic state of
the target cells (that is, activated versus quiescent); the
presence of specific growth factors and cytokines in the
microenvironment or of other cellular sources of ROS or
HNE; and the concomitant generation of NO in the
microenvironment, which may inhibit PDGF-BB-stimu-
lated proliferation through enhanced synthesis of PGE2
and cAMP [337].
Redox mechanisms in immune reactions 
associated with CLDs: fuel for chronic 
inflammation and fibrogenic progression
Several lines of evidence suggest that immune responses
may have a significant role in regulating hepatic inflam-
mation in pathological settings of CLDs. As recently
reviewed for the case of ALD [249], oxidative stress can
contribute to the progression of CLDs by giving rise to
either oxidized or adducted epitopes able to elicit an
immune response that, in turn, can contribute to perpetu-
ation of chronic injury and progression of CLDs.
The first studies in this field were performed on ALD
patients by showing the existence of circulating antibodies
against different epitopes as well as infiltration of both
CD4+ and CD8+ T lymphocytes in areas of inflammation
and necrosis [249]. The first antibodies characterized in
ALD patients were originally those directed against
adducts between acetaldehyde and liver proteins [338].
However, recent studies have shown that human ALD
patients exhibit significant titres of circulating antibodies
directed against a number of epitopes modified by free
radicals or oxidative stress reactive intermediates
[249,339]. At present, the best characterized examples ofFibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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Intracellular generation of ROS in human HSC/MFs exposed to PDGF-BB or to hydrogen peroxide Figure 28
Intracellular generation of ROS in human HSC/MFs exposed to PDGF-BB or to hydrogen peroxide. Detection of intracellular 
generation of ROS was performed by using the conversion of 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) probe in 
human HSC/MFs. Experimental conditions included control cells and cells treated with PDGF-BB (10 ng/ml) or H2O2 (50 μM, 
positive control) for 15 minutes. Cells were observed and photographed under a Zeiss fluorescence microscope equipped with 
phase contrast objectives. Images of the same fields were collected and images in the right column offer, for all conditions, the 
overlay of fluorescence and phase contrast images (E Novo et al, unpublished data).
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these oxidized or modified epitopes, recognized by circu-
lating antibodies (usually IgG), are: various adducts
between liver proteins and hydroxyl-ethyl radicals
(HERs), with circulating antibodies recognizing particu-
larly HER-CYP2E1 adducts [249]; various proteins
(mostly not identified) modified by end-products of lipid
peroxidation, such as HNE, MDA or lipid hydroperoxides,
with titres of related circulating antibodies more prevalent
in patients with an advanced stage of ALD [340]; and
lysine residues in proteins modified by the combined
reaction of MDA and acetaldehyde, leading to the forma-
tion of highly antigenic products that have been defined
as malonaldehyde-acetaldehyde adducts [341,342].
Indeed, as many as 35% of patients with an advanced
stage of ALD (but not heavy drinkers with steatosis only)
show the presence of a T cell proliferative response against
lipid peroxidation protein adducts [340,343], suggesting
that oxidative modifications of epitopes may promote
both humoral and cellular immune responses.
Circulating IgG able to recognize epitopes modified by
lipid peroxidation-derived reactive molecules has also
been detected in patients with NAFLD or affected by
chronic hepatitis C [249,344,345], indicating that the sce-
nario is of more general value. When NAFLD patients
were compared to control subjects, a significantly
increased titre of IgG directed against protein adducted
with MDA or arachidonic acid hydroperoxide or oxidized
cardiolipin was found. The presence of these antibodies in
NAFLD patients was independent of age, body mass
index, transaminase levels, and the extent of steatosis or
the concomitant presence of diabetes. Metabolic changes
leading to hepatic steatosis can indeed affect immune
functions, possibly by down-regulating the number of
liver regulatory T cells, predominantly those with a Th1
cytokine pattern; moreover, adipokines released by adi-
pose tissue have been suggested as additional factors able
to affect the regulation of inflammatory and immune
response [346,347].
A very similar scenario (that is, increased titres of IgG
against human serum albumin adducted against MDA,
HNE, arachidonic acid hydroperoxide and oxidized cardi-
olipin) has been described in patients affected by chronic
hepatitis C. The titres of these antibodies were signifi-
cantly increased in chronic HCV patients in relation to
alcohol intake, but significant increases in these titres was
reported even for those patients having only a modest
alcohol intake [345]. This study also pointed out that
those chronic HCV patients who were also heavy drinkers
had statistically significantly more piecemeal necrosis and
fibrosis than non-drinkers. Moreover, diffuse piecemeal
necrosis was approximately four-fold more frequent in
patients who consumed ethanol and had high titres for
these antibodies than among patients whose antibody
titres were within the control range. Thus, even moderate
ethanol consumption can promote oxidative stress in
chronic HCV patients, eliciting an immune response that
is likely to contribute to the already well known ethanol-
dependent worsening of the disease.
With regard to NAFLD patients, the scenario is not com-
pletely applicable, with titres of lipid peroxidation-related
antibodies apparently unrelated to histological signs of
necro-inflammation. However, a carefully performed sta-
tistical analysis has revealed that both titres and the fre-
quency of these antibodies were significantly higher in
NAFLD patients with bridging fibrosis or cirrhosis com-
pared to patients with no fibrosis or just mild levels of
pericellular/perilobular fibrosis [344]. This suggests that
the presence of oxidative stress-triggered immune reac-
tions could be an independent predictor of NAFLD pro-
gression to an advanced stage of fibrosis and then, likely,
as a mechanism potentially contributing to NAFLD pro-
gression to NASH.
Mechanisms that may be involved in the development of
immune responses to oxidative stress-modified antigens
are rather complex and have been recently discussed in
detail for the specific case of ALD [249], with an emphasis
on the unique liver immunological properties and the
crucial and dual role of Kupffer cells. These resident mac-
rophages are indeed able to down-regulate under physio-
logical conditions antigen presentation and T cell
activation by releasing TNF, IL-10 and ROS. However,
they can also do the opposite in alcoholics exposed to
high levels of LPS by releasing IL-12 and IL-18, which can
recruit natural killer T cells as well as both CD8+ and
CD4+ lymphocytes. Moreover, one should note that
hepatic stellate cells may contribute to recruitment of
these cells since they have been described to act also as
antigen presenting cells [348,349]. The interested reader
can find more details in specialized reviews [249,348-
351], and Figure 29 summarizes just those mechanisms
and events involved in the redox-dependent development
of autoantibodies and in mediating hepatocyte cell death.
Oxidative stress-mediated immune responses as fuel for 
inflammation and fibrogenesis
In CLDs, with ALD patients being a reference for the
amount of evidence available, oxidized or modified
epitopes may induce humoral as well as cell-mediated
immune responses able to significantly contribute to the
maintenance of hepatic inflammation in the natural his-
tory of ALD. This is crucial in the specific ethanol-related
scenario that is often dominated by increased transloca-
tion of LPS and endotoxins from the gut to the portal cir-
culation (and the consequent effect on Kupffer cells) and
with regard to the fact that ethanol-derived oxidative
stress can increase the hepatotoxic action of TNF: indeed,Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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in either chronically ethanol fed rats or alcoholics the
presence of high titres of IgG against antigens modified by
lipid peroxidation or oxidative stress correlate well with
increased TNF production and, quite reasonably, the
severity of inflammatory infiltrate [249].
One can envisage a scenario in which, in the presence of
continuous antigen stimulation, cytokines released by
lymphocytes can actively sustain Kupffer cell-mediated
release of cytokines and chemokines as well as of ROS and
NO, which, in turn, may contribute to the perpetuation of
oxidative injury, the inflammatory response and fibrogen-
esis. Interestingly, as many as 60”80% of ALD patients
with an advanced stage of the disease have significantly
increased levels of anti-phospholipid autoantibodies
(aPL-Ab) that recognize oxidized cardiolipin and phos-
phatidylserine (reviewed in [249]). aPL-Ab, by recogniz-
ing and binding to specifically oxidized epitopes in
apoptotic hepatocytes (not in living cells, with phosphati-
dylserine being oxidized during apoptosis and before
exposure on plasma membranes), may affect the ability of
Kupffer cells to recognize and phagocytose apoptotic cells.
Since phagocytosis of apoptotic cells usually involves
increased release of TGFβ1 and IL-10 and down-regula-
tion of TNF and IL-12 production, an impaired disposal of
apoptotic hepatocytes by Kupffer cells will negatively
affect the anti-inflammatory response of Kupffer cells.
Moreover, Kupffer cells as well as other phagocytes may be
further activated (pro-inflammatory) by increased recog-
nition of aPL-Ab bound to the surface of apoptotic cells
Redox-dependent development of autoantibodies against oxidative stress-modified epitopes Figure 29
Redox-dependent development of autoantibodies against oxidative stress-modified epitopes.
A nice scenario for generation of autoantibodies against CYP2E1 in ALD patients, here offered as a 
paradigmatic model, has been outlined [249] that involves the following steps:  
a) the alkylation of the cytochrome by hydroxyethyl-radicals (HERs) during ethanol metabolism in 
chronic patients; 
b) CYP2E1-HERs may up-regulate an autoimmune response as a consequence of phagocytosis of 
irreversibly injured hepatocytes by APCs (possibly including also HSCs); however, one should also 
remind that hepatocytes themselves may present antigens since under stimulation by pro-
inflammatory cytokines they have been reported to express class II antigens of MHC and CD-80 
[350]; then professional APCs, HSCs or hepatocytes may present these oxidized epitopes to CD4+ 
T lymphocytes;
c) oxidative stress may favour the activation of quiescent CD4+ T lymphocytes to autoreactive cells 
that, in turn, can lead to both the expansion of B lymphocytes producing IgG also recognizing native 
CYP2E1 as well as to the generation of autoreactive CD8+ cells; in this connection, it has been 
proposed that oxidative stress in liver steatosis (then a  condition common to ALD and NAFLD but 
also often found in HCV patients) may promote the apoptosis of liver regulatory T cells [351] and 
that oxidative stress - mediated immune response may be sustained also by the characteristic 
predominance of a Th1 response in relation to steatosis [249]; still related to the prevalence of Th1 
cytokine pattern, it should be stressed again that an additional role may be also played by changes 
in the levels of adipokines like adiponectin and leptin, that have been proposed to modulate both 
inflammatory and immune response; 
d) since CYP2E1 has been reported to be also expressed at the level of hepatocyte plasma 
membrane, the final step here is then represented by immune-mediated hepatocyte death that can 
involve both CYP2E1-autoreactive CD8+ T lymphocytes as well as to an antibody - dependent cell
cytotoxicity (ADCC).  Fibrogenesis & Tissue Repair 2008, 1:5 http://www.fibrogenesis.com/content/1/1/5
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through the IgG Fc receptors. Finally, impaired disposal of
apoptotic cells and/or bodies may, at the same time: fur-
ther increase the inflammatory response because of post-
apoptotic cell lysis; maintain conditions that further sus-
tain development of aPL-Ab; and act as a pro-fibrogenic
stimulus, as shown by already cited studies in which
phagocytosis of apoptotic bodies by HSC/MFs resulted in
the NOX- and ROS-dependent increased stimulation of
pro-collagen type I synthesis [97,322].
Antioxidants as antifibrotic therapeutics for 
CLDs?
This section offers some comments on the potential use-
fulness of antioxidants as therapeutic agents. Since the lit-
erature on this topic is impressive, we offer here just a
number of take-home messages (for more detail, see
[35,36,78,352-354] and the references therein). The first
message is unequivocal: antioxidants significantly prevent
experimental liver fibrosis and its progression toward cir-
rhosis by inhibiting recruitment of inflammatory cells, the
number of MFs, and levels of pro-inflammatory and pro-
fibrogenic cytokines. This statement applies to different
animal models of CLDs and to both naturally occurring
and synthetic antioxidants that differ in structure and
mechanism of action. The list of effective antioxidant
strategies employed in animal models of fibrosis is
impressive [35,36,77,80,352], including treatment with
α-tocopherol, carotenoids, the selenium antioxidant ebse-
len, hydroxyl radical scavengers (such as dimethylsul-
phoxide of dimethylthiourea), N-acetyl-cysteine, several
flavonoids and polyphenols (such as silymarin, quercetin,
curcumin, epigallocatechin, and so on), the Japanese
herbal medicine sho-saiko-to, the GSH-replenishing com-
pound S-adenosyl methionine, the CYP2E1 inhibitor
diallyl sulphide and the supernutrient polyenylphos-
phatidylcholine.
Unfortunately, results from clinical trials [35,36,78,352-
354] are definitively less impressive in terms of changes in
laboratory data (some trials report a significant decrease
in serum alanine aminotransferase (ALT) levels and few
other 'positive' features on selected liver parameters), his-
tological appearance and survival rate. No convincing sig-
nificant decrease of liver fibrosis has been documented so
far, with just the possible exception of some trials with
NAFLD/NASH patients treated with vitamin E ([353,354]
and references therein). If one has to outline the possible
reasons for such an evident discrepancy between experi-
mental and clinical results, the following may apply.
Experimental protocols have usually been designed to
make the antioxidant molecule available from the begin-
ning of the protocol, whereas in clinical trials antioxidants
have been administered mainly to patients with estab-
lished cirrhosis or with an advanced stage of CLD; this is
relevant if one considers that oxidative stress (as stressed
in this review) is likely to represent a constant pro-fibro-
genic feature in the natural history of any CLD. Also, in
order to match the effective antifibrotic doses employed
in experimental studies, human patients should receive
very high doses of these compounds, which are either
intrinsically difficult to reach or, for some compounds,
may raise serious toxicity concerns.
A number of strategies may help to overcome these prob-
lems. A first concept is that early diagnosis of the CLD
should reasonably allow administration of safe antioxi-
dants as soon as possible during the natural history of the
disease to slow down its fibrotic progression. Alterna-
tively, we should use strategies that lead to increased avail-
ability of candidate antioxidants with sufficiently rapid
rate constants as to be pharmacologically active (that is,
even at low doses). Theoretically, at least two different
strategies should be tested in properly designed trials:
first, the use of more powerful antioxidant molecules,
such as flavonoids/polyphenols and/or active principles
of herbal compounds, which may also affect fibrotic pro-
gression as a consequence of their putative 'signalling'
properties able to counteract HSC activation
[35,36,77,80,352,355]; and second, the use of transfec-
tion strategies to deliver antioxidant enzymes such as
superoxide dismutase, thioredoxin or heme oxygenase-1
directly to the injured parenchyma or, even more specifi-
cally, to HSCs (proof of principle of the efficacy of these
strategies has already been reported in experimental mod-
els [356-358]).
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